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Abstract 
Background 
NICE is an independent organisation responsible for providing national guidance on the 
promotion of good health and the prevention and treatment of ill health in England and 
Wales. One of NICE’s main roles is to produce national guidance on the use of health 
technologies within the NHS. Despite the Institute’s recent efforts to clarify the way in 
which its Appraisal Committees reach their recommendations concerning the use of 
health technologies, there remains ambiguity about how cost-effectiveness evidence is 
interpreted alongside other considerations such as the degree of clinical need within the 
patient population, and the degree of uncertainty surrounding cost-effectiveness 
estimates. 
 
Objective 
To explore whether the NICE takes account of factors such as uncertainty and equity as 
well as incremental cost-effectiveness in commissioning health care services.  
 
Methods 
A binary choice experiment was undertaken using NICE’s three Appraisal Committees. 
The experiment included five attributes: 
(1) Incremental cost-effectiveness 
(2) Degree of economic uncertainty 
(3) Age of the target population 
(4) Baseline health-related quality of life 
(5) Availability of other therapies 
 
A choice questionnaire detailing 18 scenarios was administered to NICE’s Appraisal 
Committees. For each scenario, respondents were asked to indicate whether they would 
recommend the intervention under consideration or not. The stated preference data 
obtained from respondents were analysed using a random effects logit regression model. 
 
Results 
A response rate of 46% was obtained from the Appraisal Committees. The regression 
model suggests that increases in cost-effectiveness, economic uncertainty, and the 
availability of other therapies are associated with statistically significant reductions in 
the odds of adoption (p<0.05). The transition from a very low to a comparatively high 
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level of health-related quality of life is also associated with a statistically significant 
reduction in the odds of a positive recommendation. Smaller changes in health-related 
quality of life, and the age of the target population are not associated with a statistically 
significant reduction in the odds of a positive recommendation. Analysis of revealed 
preference data indicates that the model is capable of distinguishing between those 
technologies which the Appraisal Committees would be highly likely to recommend, 
and those technologies which appear to be less attractive, although further external 
validation is warranted. 
 
Conclusion 
The modelling suggests that cost-effectiveness, uncertainty and certain equity concerns 
influence the NICE Appraisal Committees’ recommendations on the use of health 
technologies. The modelling results appear to support Rawlins and Culyer’s notion of a 
probabilistic cost-effectiveness threshold approach; the “mythical” £30,000 per QALY 
gained threshold assumed within the literature is not supported by this stated preference 
modelling analysis. 
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Chapter 1  Introduction 
1.1 Background 
The National Institute for Clinical Excellence was established as a Special Health 
Authority in 1999 following the publication of the Government White Paper “The new 
NHS modern, dependable.”1 The Institute’s successor, the National Institute for Health 
and Clinical Excellence (NICE), is an independent organisation responsible for 
providing national guidance on the promotion of good health and the prevention and 
treatment of ill health in England and Wales.2 One of the Institute’s main functions is 
the appraisal of new and existing health technologies. Recommendations to the National 
Health Service (NHS) concerning the use of specific health technologies are prepared 
by one of three independent Appraisal Committees. Each Appraisal Committee consists 
of health professionals working in the NHS and people who are familiar with the issues 
affecting patients and carers.2  
 
During the appraisal of each health technology, the Appraisal Committee is presented 
with evidence relating to the epidemiology and pathophysiology of the condition for 
which the technology is indicated, estimates of the clinical effectiveness and cost-
effectiveness of the intervention compared to current standard treatments, the degree of 
uncertainty surrounding mean costs and effects, the characteristics of the relevant 
patient group who will benefit from the intervention, and the position of the technology 
within current clinical pathways. 
 
Despite the Institute’s recent efforts to clarify the way in which NICE’s Appraisal 
Committees reach decisions concerning the recommendation for or against the use of 
health technologies, in particular, the role of scientific and social value judgements,3-5 
there remains ambiguity concerning how cost-effectiveness evidence is interpreted 
alongside other attributes such as the degree of clinical need within the patient 
population, and the degree of uncertainty surrounding cost-effectiveness estimates. 
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1.2 Study aims and objectives 
The main aim of this study is to address the question: “Does the National Institute for 
Health and Clinical Excellence take account of factors such as uncertainty and equity 
as well as incremental cost-effectiveness in commissioning health care services?” 
 
More specifically, the objectives of the study are: 
(1) To explore current literature concerning the way in which NICE uses evidence on 
uncertainty and equity considerations alongside cost-effectiveness when making 
recommendations concerning the use of health technologies;  
(2) To undertake a binary choice experiment to examine whether NICE takes into 
account uncertainty, age, baseline health-related quality of life (HRQoL) and the 
availability of other therapies alongside cost-effectiveness in commissioning health 
technologies; 
(3) To estimate the relative importance placed on various programme attributes by 
NICE’s Appraisal Committees. 
 
1.3 Research design 
The primary research element of the study takes the form of a binary choice experiment. 
The preferences of members of NICE’s Appraisal Committees were elicited within a 
controlled experiment using five programme attributes:  
(1) Incremental cost-effectiveness  
(2) Degree of economic uncertainty 
(3) Age of the target population 
(4) Baseline HRQoL of the target population 
(5) Availability of other therapies 
 
A choice questionnaire detailing 18 scenarios was administered to each of the three 
NICE Appraisal Committees. For each choice scenario, respondents were asked to 
indicate whether they would be likely to recommend the intervention under 
consideration or not. The choice experiment explores whether and how other 
programme attributes such as uncertainty and equity considerations are traded off 
against cost-effectiveness when making health care commissioning decisions. 
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1.4 Structure of report 
Chapter 2 presents a review of some existing literature relating to the decision-making 
criteria employed by NICE’s Appraisal Committees. Evidence supporting and opposing 
the existence of a cost-effectiveness threshold for the adoption/rejection of health 
technologies is discussed. Evidence relating to the interpretation and potential influence 
of other attributes such as uncertainty, equity and the role of social value judgements is 
also presented. Gaps in current knowledge concerning the NICE Appraisal Committees’ 
decision-making criteria are highlighted. 
 
Chapter 3 reports the methods for the design and analysis of the binary choice 
experiment. The chapter outlines the identification and selection of attributes and levels 
used within the choice experiment. Issues surrounding sample size and sampling 
designs are highlighted within the chapter. Methods for random effects logit and probit 
regression analysis using the elicited stated preference data are detailed. An assessment 
of internal and external validity is also reported. Trade-offs between ideal and practical 
experiment designs are discussed. 
 
Chapter 4 details the results of the binary choice experiment analysed using regression 
modelling. Sensitivity analysis is reported using a subset of choice scenarios included in 
the questionnaire. The results of the assessment of logical consistency are detailed. An 
assessment of external validity using a limited sample of revealed preference data from 
previous NICE appraisals is also presented. 
 
Chapter 5 presents a discussion of the results of the study in the light of previous 
research concerning NICE’s decision-making criteria. Limitations of the study are 
discussed. Areas in which further research is merited are highlighted. 
 
Chapter 6 presents the conclusions of the study. 
 
Appendix 1 presents the choice questionnaire employed within the experiment. 
Appendix 2 contains the study outline and process presented to the NICE Appraisals 
Committees. 
Appendix 3 presents the letter of approval obtained from the University of Sheffield 
Research Ethics Committee. 
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Chapter 2 Review  
2.1 Introduction 
The NHS was founded on three broad principles: that health care advice, treatment and 
care should be available to all who need it; that patients shall receive the best medical 
and other facilities available; and that individuals should receive these irrespective of 
whether they can pay for them.6 From these principles, at least two key objectives can 
be identified: efficiency and equity. Broadly speaking, the former draws from 
utilitarianism principles of the greatest good for the greatest number of people; technical 
and allocative efficiency could be realised through the maximisation of health gains 
across a population. The latter is a more difficult concept to define, drawing from 
principles of justice and fairness, and concerns the fair distribution of costs and 
consequences within and across socioeconomic groups. It follows then, that decision-
making within the NHS should be consistently aimed at the achievement of both these 
key objectives. However, one cannot escape the fact that health resources are scarce and 
humans are increasingly demanding.7 In practice, the maximisation of health gains may 
be at the expense of the equitable distribution of the costs and benefits, or alternatively, 
the achievement of a fair distribution of costs and health gains across various population 
groups may be at the expense of health gain maximisation. 
 
How then, should decisions be made concerning the allocation of scarce health care 
resources, whereby health gains are maximised and distributed in a fair and just 
manner? The existence of multiple and potentially conflicting objectives within the 
constraint of scarce health care resources means that NHS prioritisation decisions are 
invariably complex. Consequently, the NHS and other health care systems require some 
rational, transparent and explicitly justified approach to the prioritisation and allocation 
of health care resources.8;9 This review explores the factors that may influence how 
decisions concerning the prioritisation of health technologies are currently made.  
 
2.2 Background to NICE 
NICE was established in 1999 to provide patients, health professionals and the public 
with authoritative, robust and reliable guidance on current best clinical practice. 2 NICE 
produces national guidance in three areas of health: 
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(1) Public health. NICE produces guidance on the promotion of good health and the 
prevention of ill health for those working in the NHS, local authorities and the 
wider public and voluntary sector; 
(2) Clinical practice. NICE produces guidance on the appropriate treatment and care 
of people with specific diseases and conditions within the NHS; 
(3) Health technologies (pharmaceuticals, medical devices, diagnostic techniques, 
surgical procedures, other therapeutic interventions and health promotion 
activities). NICE produces guidance on the use of new and existing medicines, 
treatments and procedures within the NHS.2 Through the establishment of 
national guidelines based on current best available evidence, NICE attempts to 
eliminate the use of ineffective treatment approaches and release resources for 
the equitable provision of cost-effective health care interventions.10 
 
2.3 The Technology Appraisal Process 
This review focuses on those decisions concerning the prioritisation of health 
technologies. NICE’s guidance on the use of technologies is based upon the formal 
appraisal of scientific and non-scientific evidence on the use of health technologies. 
Technologies to be appraised are formally referred to NICE by the Secretary of State for 
Health and the Welsh Assembly Government. Following each appraisal, NICE issues 
guidance on the use of the technology to the NHS in England and Wales. Upon its 
establishment, the Institute’s recommendations were advisory, however, since 2002 the 
Secretary of State has directed that the NHS is required to provide funding and 
resources for medicines and treatments recommended by NICE through its technology 
appraisals work programme. The NHS normally has three months from the date of 
publication of each guidance document to provide such funding and resources.11 At the 
time of writing, NICE had published guidance following 92 health technology 
appraisals. 
 
Technology appraisals consider evidence relating to the expected health benefits and 
costs resulting from the use of individual or groups of health technologies in usual 
clinical practice. Health benefits typically include impacts upon mortality and HRQoL, 
measured in terms of quality adjusted life years (QALYs). Expected costs of the 
technology relate to those directly incurred by the NHS and Personal Social Services 
(PSS).  
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The Institute considers scientific evidence from an independent assessment of the 
clinical and cost-effectiveness of the technology, together with submissions from the 
technology’s manufacturer and other consultees such as clinical experts and patient 
representative groups. Non-scientific evidence such as anecdotal patient accounts is also 
considered.12 Following consideration of all relevant available evidence, the Appraisal 
Committee reaches a judgement as to whether, on balance, the technology can be 
recommended as a cost-effective use of NHS resources in general, or whether it can be 
recommended for specific indications or subgroups of patients.12 The Appraisal 
Committee then submits an “Appraisal Determination” to the Institute, which forms the 
basis of NICE’s guidance on the use of the technology. 
 
In reaching decisions on whether to recommend health technologies, the Institute and its 
Appraisal Committees take into account the factors listed in the directions of the 
Secretary of State for Health and the Welsh Assembly Government,12 namely: 
· the broad clinical priorities of the Secretary of State for Health and the Welsh 
Assembly Government (e.g. as set out in National Service Frameworks);  
· the degree of clinical need of the patients with the condition under 
consideration; 
· the broad balance of benefits and costs; 
· any guidance from the Secretary of State for Health and the Welsh Assembly 
Government on the resources likely to be available and on such other matters as 
they think fit; 
· the effective use of available resources. 
 
The Institute also takes into account the longer-term interests of the NHS in 
encouraging innovation in technologies that will benefit patients. 
 
2.4 The NICE Appraisal Committees  
The Institute currently has three Appraisal Committees, consisting of a total of 81 
members. These committees are independent advisory bodies that make 
recommendations concerning the clinical and cost-effectiveness of treatments for use 
within the NHS, as well as recommending against those therapies whereby the benefits 
to patients are either unproven or not cost-effective. The Appraisal Committee’s 
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judgements on clinical effectiveness take account of the nature and quality of several 
sources of evidence. These include the clinical analysis undertaken by the Assessment 
Group and the manufacturers of the technology, as well as the views of specialists, 
patients and their representative groups.13 The Appraisal Committee also consider 
uncertainty relating to differences in the effectiveness of the technology between 
clinical evidence submitted for licensing purposes and usual clinical practice, 
differential effectiveness or risks of adverse events for specific patient groups, the 
position of the technology in the overall pathway of care and whether alternative 
effective treatments are available.13 
 
However, the clinical effectiveness of a technology is a necessary but not sufficient 
condition for the Appraisal Committee to recommend its routine use on the NHS; the 
Appraisal Committees are also required to consider whether the technology represents 
good value for money. According to recent methodological guidance,13 the Committees’ 
judgements on cost-effectiveness include consideration of economic models submitted 
by both the Assessment Group and the manufacturers of the technology, including their 
structure, the plausibility of assumptions, the evidence inputs and outputs, and the 
Committee’s preferred modelling approach. During their deliberations, the Appraisal 
Committee determines the central estimate of cost-effectiveness and whether they 
consider this to be acceptable, and reviews evidence relating to the uncertainty 
surrounding mean costs and health effects.13 The Appraisal Committees do not consider 
the affordability of the technology, as this lies within the remit of the Department of 
Health, although consideration is given to how its advice may enable the more efficient 
use of available health care resources.13 
 
A central principle underlying NICE’s decision-making approach is that best practice 
can be determined in a way which is applicable across the whole system.10 Public 
documents concerning how NICE conducts health technology appraisals suggest that a 
broad range of clinical and economic issues are consistently considered when deciding 
whether or not to recommend technologies for use on the NHS. The central issue does 
not concern whether the relevant attributes of technologies are considered, but rather 
how such information should be addressed within a consistent, rational framework in 
order to satisfy the objectives of the NHS. The credibility of NICE’s guidance is 
dependent on the transparency of the Appraisal Committee’s decision-making process. 
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It is crucial that the Appraisal Committee’s decisions are consistent across the broad 
range of health technology appraisals undertaken, and that the views of consultees to the 
appraisal are taken into account. Only through the application of a coherent and explicit 
approach can NICE successfully achieve the central objectives of the NHS. 
 
2.5 The use of health economic evidence to prioritise health care 
resources 
2.5.1 The role of economic evaluation in the prioritisation of health care 
resources  
The application of economic evaluation to clinical procedures and health technologies 
to directly or indirectly inform resource allocation decisions is not new. Economic 
evaluations of health interventions have been used to inform decision-making since the 
1960s.10 Indeed, NICE’s use of economic criterion to inform health resource allocation 
decisions is not unique; in other countries, such economic evaluations are used for a 
variety of decision-making purposes. A number of governments including those of 
Australia, New Zealand, Finland, Norway, and the Canadian provinces of Ontario and 
British Columbia now require the submission of economic evidence when making 
recommendations for the purchase of pharmaceuticals.14 In Portugal, Denmark and 
France, pharmaceutical companies may be asked to submit health economic evidence 
when a reimbursement decision is to be made, although such power is used only on a 
discretionary basis.14 The role of such economic evidence in government decision-
making includes informing “yes/no” reimbursement decisions, exerting downward 
pressures on product prices, and establishing price-volume agreements.14 
 
Few would argue against the relevance of economics in health care commissioning 
decisions. An editorial published in the New England Journal of Medicine argued that a 
physician who allows cost issues to affect their decision-making has “embarked on the 
‘slippery slope’ of compromised ethics and waffled priorities.”15 However, owing to the 
inevitable scarcity of health care resources, failure to consider cost implications of 
treatments may lower quality of care and harm the health of patients. 16 It follows then, 
that resource allocation decisions that are made without the consideration of opportunity 
cost may be ethically irresponsible.  
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2.5.2 Theoretical use of economic evidence to prioritise health care 
resources 
Economic evaluation provides one means of informing difficult decisions about which 
services treatments should receive priority. Budget-holders can use cost-effectiveness 
analyses to maximise health gains from the allocation of limited resources.10 Cost-
effectiveness evidence has been considered within the vast majority of technology 
appraisals undertaken by NICE. Of the 92 health technology appraisal guidance 
documents currently available on the Institute’s website, 68 guidance documents report 
cost-effectiveness estimates or the use of a cost-effectiveness model, 55 of which were 
undertaken within a cost-utility framework (this excludes the 15 appraisal guidance 
reports which have become obsolete). Notably, the use of cost-effectiveness analysis 
and cost-utility analysis to inform NICE technology appraisals appears to be increasing 
over time. However, there remains ambiguity concerning how cost-effectiveness 
evidence should be used to inform prioritisation decisions. Whilst the methods for 
undertaking cost-effectiveness analysis are well developed, efforts expended in ensuring 
the appropriateness of health care decision-making have been relatively limited. 
 
If the fundamental premise of health technology assessment is to maximise the total 
aggregate health benefits conferred for any given level of available resources, 17 one is 
led directly to a mathematical optimisation solution: the maximisation of health benefits 
subject to the financial and resource constraints of a fixed budget. This optimisation 
problem highlights three relevant interrelated concepts: (1) the total health budget 
expenditure, (2) the cost-effectiveness acceptability threshold (or the amount of money 
society is assumed to be willing to pay for a given level of health benefit); and (3) the 
overall system efficiency.   
 
Overall system efficiency could be optimised through two alternative approaches, 
depending on whether the budget constraint is fixed or variable. Assuming a fixed 
budget constraint, listing all technologies within a “league table”,17;18 and purchasing all 
interventions in order of their declining cost-effectiveness until funds have been 
exhausted will maximise the aggregate health benefits achieved and hence maximise the 
overall system efficiency. Under this system, the cost-effectiveness acceptability 
threshold is allowed to vary, and is thus defined by the cost-effectiveness of the last 
intervention purchased. Alternatively, given a fixed cost-effectiveness acceptability 
  10
   
threshold constraint, purchasing only those interventions that demonstrate an 
incremental cost-effectiveness better than the threshold will minimise the total 
expenditure and thus maximise the overall system efficiency. The necessary implication 
is that the partial implementation of both approaches, fixing both the budget and 
threshold independently and without respect to each other, will inevitably lead to 
overall system inefficiency, and in turn, the achievement of an inefficient distribution of 
health care resources.  
 
Whilst the process of priority-setting across a spectrum of alternative programmes using 
the league table approach18;19 described above appears intuitively attractive and has 
some proponents,20 it is subject to several important problems. Information on the costs 
and effects of health interventions are imperfect, and the construction of a league table 
for all health interventions is currently unrealistic.18;19 In addition, the usefulness of 
league tables is severely limited by the non-comparability of methods used to derive 
cost-effectiveness estimates, together with heterogeneity in methods for the valuation of 
HRQoL and costs. NICE has recently defined a “Reference Case” for cost-effectiveness 
analyses; this specifies the methods which are currently considered by the Institute to be 
the most appropriate for decision-making purposes and which are believed to be 
consistent with the NHS’s objective of maximising health gains from limited 
resources.13 Whilst the establishment of NICE’s Reference Case may help the Institute 
to make consistent decisions across different technologies and health conditions, at 
present this does not represent the complete implementation of a formal cost-
effectiveness league table approach.  
 
A further problem of the league table approach is that estimates of incremental cost-
effectiveness may be influenced by the interests of those undertaking the analysis. A 
recent review of cost-effectiveness analyses undertaken for the purposes of NICE 
Appraisals found that incremental cost-effectiveness ratios submitted by the 
manufacturers of technologies under appraisal were, on average, statistically 
significantly lower (more favourable) than those submitted by the independent 
Assessment Groups.21 
 
Even if an all-encompassing cost-effectiveness league table were possible, and potential 
biases and heterogeneities could be suppressed or minimised, the resulting resource 
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allocation decisions would not take account of who receives the health benefits or how 
they are distributed across society. 
 
2.5.3 Interpretation of cost-effectiveness evidence – does NICE operate a 
cost-effectiveness threshold?  
NICE’s decision-making has been criticised on account of the Institute’s ignorance of 
the principle of opportunity cost.22 It has further been suggested that “if economics is 
not established as the underlying decision making framework for NICE, the credibility 
of microeconomic evaluation in health care may be seriously disabled.”.10 If 
transparency in decision-making is desired, it is crucial for NICE to be explicit about 
the way in which it uses cost-effectiveness evidence. Indeed, decisions concerning 
whether technologies represent good value for money require comparisons with some 
benchmark or threshold, as the notion of “cost-effectiveness” cannot exist in isolation. 
In line with theoretical approaches to resource allocation on the basis of economic 
evaluation, it has been suggested that NICE operates a cost-effectiveness threshold, 
whereby interventions that demonstrate an incremental cost-effectiveness that is better 
than the threshold are accepted, whilst those interventions that are less cost-effective 
than the thresholds are rejected, as shown in Figure 1. 
 
Figure 1 Fixed threshold approach to decision-making (based on Devlin and 
Parkin23) 
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A recent review of the Institute’s technology appraisals by the World Health 
Organisation (WHO) stated that if a threshold is to be used as the basis for NICE’s 
recommendations, this needs to be specified and justified for reasons of transparency.24 
It is important that NICE is clear about how other objectives should be recognised and 
traded off against evidence on cost-effectiveness within their decision-making process. 
Since its inception, much of the discussion surrounding NICE’s decision-making 
criteria has focussed on whether a threshold exists, what value that threshold takes, and 
what value the threshold should take. Considerably less attention has been placed on 
how NICE actually interprets cost-effectiveness evidence alongside other considerations 
in order to satisfy the multiple objectives of the NHS. 
 
2.5.4 Empirical evidence for the existence of a threshold 
NICE’s formal position is that the Appraisal Committee does not use an “immutable” 
cost-effectiveness threshold.3-5;13;25 However, comments from NICE on the existence of 
a cost-effectiveness threshold appear to be contradictory. Public comments made in 
2001 by Sir Michael Rawlins, NICE’s Chairman, indicated that a threshold of £30,000 
per QALY gained had emerged from the Committee’s deliberations, although the 
Institute subsequently submitted evidence to the House of Commons Health Select 
Committee claiming that comments relating to the existence of the threshold were 
misinterpreted.26 In further support of the operation of a formal cost-effectiveness 
threshold, recent NICE guidance on the use of Orlistat (Xenical®, Roche 
Pharmaceuticals) for the treatment of obesity in adults stated that a “sufficient level of 
cost-effectiveness” is “in the range of a cost per QALY gained of between £20,000 and 
£30,000.”27 
 
In 2001, Raftery undertook review of NICE guidance on 22 technologies according to 
the three criteria initially outlined in NICE’s requirements for submissions of evidence, 
namely, cost per QALY, clinical benefits, NHS budget impact.28 Raftery commented on 
the difficulty in establishing how the balance between clinical benefits and economics 
had influenced NICE recommendations.28 A cost per QALY estimate was cited within 
50% of guidance documents. Raftery notes that whilst a cost per QALY estimate may 
have been available from the manufacturers or Assessment Group within the remaining 
50% of appraisals, the Appraisal Committee’s decision not to cite a cost-effectiveness 
estimate suggests that they did not find available economic evidence convincing, thus 
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the basis of their recommendations was unclear.28 Of those guidance documents in 
which a cost per QALY was cited, all but one technology (Riluzole, Rilutek®, Aventis 
Pharma) had a cost per QALY below £30,000 and subsequently received positive 
recommendations from the Committee (although Riluzole was apparently recommended 
on the basis of “the value patients place on tracheostomy free survival time”29). 
Raftery’s review highlighted that NICE have generally said “yes, but…”, whereby 
positive recommendations were accompanied by specified conditions for the use of 
technologies. 
 
In 2004, Devlin and Parkin undertook a binary choice analysis using retrospective 
NICE guidance reports to explore how the characteristics of health technologies operate 
to influence NICE’s decision-making, and to establish the characteristics of NICE’s 
cost-effectiveness threshold.23 The authors abstracted data from guidance reports on 39 
technologies which corresponded to 51 “yes/no” decisions. Data were evaluated using a 
binary logistic regression model in order to explore how cost-effectiveness, uncertainty, 
burden of disease, and the existence of alternative therapies influence the decision to 
recommend for or against individual health technologies. Devlin and Parkin’s23 analysis 
suggested that NICE’s decisions were well explained by incremental cost-effectiveness, 
with uncertainty and burden of disease explaining some of the rejection decisions where 
the incremental cost-effectiveness ratio was low, and acceptance decisions where the 
incremental cost-effectiveness ratio was high.23 The authors indicated that actual cost-
effectiveness threshold used by NICE appears to be somewhat higher than the suggested 
range of £20,000 to £30,000 per QALY gained.23  
 
However, Devlin and Parkin’s study23 was subject to several important limitations. 
Firstly, the scope of the logistic regression model was narrow and included only a 
subset of the factors considered by the NICE’s Appraisal Committees. Furthermore, 
missing data items led to the exclusion of 18 of NICE’s decisions from the analysis. 
Further limiting factors included the absence of any distinction between the 
denominator for the cost-effectiveness ratio (the analysis did not make a distinction 
between cost per QALY gained and cost per life year gained), and the weak 
representation of uncertainty surrounding costs and effects (defined as a cost-
effectiveness range divided by the central estimate of cost-effectiveness). In addition, 
where multiple cost-effectiveness estimates were available, the mean was assumed; this 
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may not reflect the actual central estimate of cost-effectiveness agreed upon by the 
Appraisal Committee. Most importantly however, the analysis included only factors 
which appear to relate to concepts of efficiency, and did not include any consideration 
of equity factors such as the age of the target population or the severity of the disease. 
Owing to these problems, the interpretation of Devlin and Parkin’s results is 
problematic. 
 
It should be brought to light that if a cost-effectiveness threshold is in operation, the 
origin of the value of that threshold remains unclear. As noted in Section 2.5.2, the 
establishment of cost-effectiveness threshold either requires judgements or evidence 
concerning the intrinsic monetary value of a QALY, and subsequent adjustments to the 
budget made available for NHS expenditure, or to allow the value of a marginal QALY 
to emerge from the priority-setting activities of budget-holders based upon a fixed NHS 
budget.30 The appropriateness of the £30,000 per QALY gained threshold assumed 
within the literature, which does not appear to have emerged from either of the 
approaches described above, is questionable (or at least it would be if the existence of 
the threshold could be confirmed). An alternative approach suggested by Williams30 is 
the adoption of a lower cost-effectiveness threshold of around £18,000 per QALY, 
which represents the estimated current per capita Gross Domestic Product. 30 However, 
Rawlins argues that such suggestions rely on judgements which carry no more or less 
authority than the collective view of the Institute’s economic advisors.5  
 
2.5.5 Empirical evidence against the existence of a threshold 
Despite some reasonably compelling empirical evidence supporting the existence of a 
cost-effectiveness threshold, or at least an acceptable range for cost-effectiveness, NICE 
has repeatedly insisted that they do not operate such a threshold. Rawlins and Culyer3 
recently attempted to clarify the way in which NICE uses cost-effectiveness evidence 
together with scientific and social value judgements, citing four reasons why NICE 
rejects the threshold framework: 
(1) There is no empirical basis for deciding at what value a threshold should be set; 
(2) There may be circumstances in which NICE would want to ignore a threshold; 
(3) To set a threshold would imply that efficiency has absolute priority over other 
objectives such as fairness; 
(4) Many of the technology supply industries are monopolies, thus a threshold 
would discourage price competition. 
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According to Rawlins and Culyer,3 the Institute makes decisions concerning the 
recommendation for or against the use of individual health technologies on a “case-by-
case” basis,3 as described by a probabilistic S-shaped acceptance/rejection curve (See 
Figure 2). Based upon this curve, as the incremental cost-effectiveness of the 
technology increases, so too does the probability of rejection. 
 
Figure 2 NICE’s empirical acceptance/rejection curve3 
 
 
 
 
 
 
 
 
 
 
 
 
 
The key points on the rejection curve are the inflexions at points A and B. According to 
Rawlins and Culyer, “NICE and its advisory bodies have taken the view that inflexion A 
occurs at around £5,000-£15,000/QALY and inflexion B at around £25,000-
£35,000/QALY. NICE would be unlikely to reject a technology with a ratio in the range 
of £5,000-£15,000 solely on the grounds of cost-ineffectiveness, but would need special 
reasons for accepting technologies with ratios over £25,000-£35,000/QALY as cost 
effective.”3 
 
According to Rawlins and Culyer,3 the main considerations in making judgements about 
whether health technologies with incremental cost-effectiveness ratios between 
£25,000-£35,000 per QALY gained are: the degree of uncertainty; the particular 
features of the condition and population using the technology (including the availability 
and clinical effectiveness of other therapies, public health issues such as communicable 
diseases, and special equity considerations); when appropriate, the wider societal costs 
and benefits; and when appropriate, reference to previous appraisals.3 
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Further clarity on the relative importance of the characteristics of health technologies is 
provided within methodological guidance recently published by the Institute,13 which 
suggests that for interventions with a “plausible” incremental cost per QALY below 
£20,000, judgements about the acceptability of the technology as an effective use of 
NHS resources are based primarily on the cost-effectiveness estimate.13 For 
interventions with an incremental cost per QALY greater than £20,000, judgements 
about the acceptability of the technology as an effective use of NHS resources are more 
likely to make more explicit reference to factors such as the degree of economic 
uncertainty, the innovative nature of the technology and the particular features of the 
condition and population receiving the intervention.13 Above an incremental cost-
effectiveness ratio (ICER) of £30,000 per QALY gained, the case for supporting the 
technology on these factors is required to be increasingly strong.13 
 
It is interesting to note that whilst the Institute has repeatedly dismissed the existence of 
a cost-effectiveness threshold as an urban myth,3;13;25;26 the rejection curve shown in 
Figure 2 indicates that two approximate, rather than absolute, thresholds are in 
operation; one for acceptance and one for rejection. Whilst Rawlins and Culyer3 have 
provided some clarity concerning how NICE interprets cost-effectiveness evidence for 
interventions which have an incremental cost per QALY gained which is either better 
than inflexion A, or worse than inflexion B, the way in which other factors may 
influence adoption decisions between A and B remains unclear. 
 
2.6 Influence of uncertainty surrounding incremental costs and 
effects 
The costs and health gains resulting from the use of health interventions are subject to 
ubiquitous uncertainty. In recent years, considerable methodological work has been 
undertaken to resolve methods for handling uncertainty, with an increasing tendency to 
move away from simplistic one-way sensitivity analyses towards more sophisticated 
descriptions of uncertainty such as cost-effectiveness planes, net benefit distributions 
and cost-effectiveness acceptability curves (CEAcc).31 These approaches provide 
information on the likelihood that each treatment option is optimal.  
 
The decision-maker’s response to uncertainty may affect their decision to accept or 
reject a health technology. For example, a technology with a low mean cost per QALY 
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may appear less attractive if it has a high probability of being dominated by an 
alternative therapy. Claxton32 argues that only expected (mean) incremental cost-
effectiveness estimates should be used within health care commissioning decisions. 
Claxton argues that information on uncertainty surrounding expected costs and effects 
should be used to make decisions concerning the prioritisation and planning of further 
research (to reduce such uncertainty).32;33 However, the Institute’s documentation on 
how the Appraisal Committees make decisions does not appear to be consistent with 
this viewpoint.13 The degree to which uncertainty surrounding expected costs and 
effects may influence adoption decisions made by the Appraisal Committee is currently 
unclear. 
 
2.7 The role of social value judgements and equity in health 
resource prioritisation 
The empirical evidence, public conjecture and formal statements from NICE indicate a 
lack of clarity concerning how the Institute incorporates other factors besides cost-
effectiveness into its decision-making processes, particularly with regard to those 
technologies which are less attractive in terms of cost-effectiveness than other health 
technologies currently funded by the NHS. Indeed, Sir Michael Rawlins has admitted 
that the Institute’s decisions are “questions of judgement, difficult to defend, difficult to 
teach,”34 and that “all decisions in the future will be based on difficult judgements” 
which have “no mathematical quantitative approach.”34 To date, the Institute has 
published three papers describing how social value judgements are incorporated into 
their decision-making processes.3-5 The broad message within all three papers is that 
social value judgements must play a critical role if resources are to be distributed 
equitably as well as efficiently.3-5 Whilst the objective of distributing health gains in a 
fair and just manner is unambiguous, the route to achieving this objective and the 
weight that should be placed upon it are unclear. 
 
The social value judgements made by the Appraisal Committees relate to their beliefs 
concerning what is good or bad for society.3 The fundamental value judgement 
underpinning NICE is that its advice to the NHS should embody values that are 
generally held by the population that the NHS serves.3 Undoubtedly, equity lies at the 
heart of the NHS; one of the principal reasons for the establishment of NICE was to 
eradicate regional problems of “postcode prescribing.”35 NICE has recently formed a 
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Citizen’s Council to ensure that the values of society are served. However, as Culyer 
notes, much of the philosophical literature on equity may not be applicable in the real 
world, and due to conflicts between alternative equity perspectives, there may be no 
single overriding equity principle to guide the distribution of health care resources. 36;37  
 
Rawlins and Culyer suggest that an assumption underlying most of the Institute’s 
recommendations is that “a QALY is a QALY is a QALY” irrespective of how may 
QALYs have already been enjoyed, how many are in prospect, age, sex, deservedness, 
and deprivation.3 This assumption essentially corresponds to the sum-ranking 
(utilitarian) approach whereby choices between alternative distributions are determined 
by the amount of well-being generated by each one. Under this principle, the 
individual’s need for health care is defined by their capacity to benefit from that care i.e. 
the greater an individual’s expected benefit, the greater their need for health care. 38 In 
this sense, an individual’s pre- and post-intervention levels of well-being have no moral 
relevance, as only the change in well-being is considered to be important.38 However, 
there may be instances whereby NICE may wish put greater priority on objectives other 
than the size of expected health gains,3 such as how those health gains are distributed. 
For example, under Rawls’ “difference principle” (more commonly referred to as the 
‘Maximin’ principle), “social and economic inequalities must be to the greatest benefit 
of the least advantaged.”39 This differs from the sum-ranking approach, as an 
individual’s need for health care is defined according to their severity of illness, hence 
resources would be devoted to the most severely ill individual.38 Other approaches to 
distributive justice have been suggested, for example “strong egalitarianism”, although 
these are seldom considered reasonable within a health policy context.  
 
The list of potential equity concerns faced by NICE is substantial. For example, greater 
emphasis may be placed on the aged, the infirm or the vulnerable, who may be 
discriminated against under the QALY maximisation principle.40 Conversely, a lesser 
weight may be placed on the aged population based on the number of QALYs already 
enjoyed (the so-called “fair innings” argument41) and the fewer QALYs they have in 
prospect. Priority may be given to those interventions which are aimed at individuals 
with a poor prognosis over those therapies aimed at individuals who enjoy a 
comparatively high quality of life.42 Perhaps, differential weightings should be applied 
depending on the size of the expected treatment effect. Alternatively, the Institute may 
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place greater weight on those therapies which are life-saving rather than those which 
merely improve a patient’s quality of life, an imperative coined by Jonsen as the “Rule 
of Rescue.”43 An additional consideration may be whether the patient is in some way 
responsible for their condition.44;45 A further practical issue is that the Institute may 
wish to place differential emphasis on interventions used to treat conditions for which 
there is no alternative effective therapy.45 
 
The list of potential equity concerns presented above is by no means exhaustive. 
Research concerning methods for weighting QALYs for different groups of individuals 
is currently underway.46 The way in which the Institute balances these equity 
considerations alongside cost-effectiveness evidence is not currently clear, and as such, 
may be difficult to defend. As Birch and Gafni critically note, “ it implies that the 
Committee will consider recommending certain technologies be available for identified 
social groups (those for whom the treatment is ‘cost-effective’), but not for others (those 
for whom the technology is not cost effective and who are not sufficiently deserving in 
the eyes of the Committee to receive the equity weighting required to make it cost 
effective). This seems less scientific and more Orwellian than one might expect for a 
National Institute for Clinical Excellence.”22 Consequently, decisions to accept or reject 
health technologies on the grounds of equity may be considered as a “cop-out.” The 
Institute has gone some way towards outlining the types of social value judgements that 
its Appraisal Committees make,3-5 although a coherent framework addressing these 
alongside cost-effectiveness evidence has not yet been formalised. 
 
2.8 Summary of current evidence on NICE prioritisation decisions 
The literature outlined within this review suggests that NICE’s Appraisal Committees 
consider a number of important factors when deciding whether to recommend health 
technologies for routine use on the NHS. Official documentation from the Institute 
indicates that decisions are not made on the basis of cost-effectiveness alone, but rather 
cost-effectiveness evidence is considered alongside evidence relating to clinical need, 
equity concerns, and decision uncertainty. However, whilst NICE appears to be 
considering those factors relevant to the realisation of both efficiency and equity 
objectives, the way in which such evidence is synthesised within a rational, consistent 
and coherent decision-making framework is not entirely clear. Current evidence 
suggests the existence of a probabilistic cost-effectiveness threshold approach, whereby 
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within a range of potentially acceptable cost-effectiveness, numerous alternative 
considerations may serve to determine whether the technology should be adopted or 
not. The key uncertainty in NICE’s decision-making rationale appears to lie between 
these inflexion points; how does NICE trade-off alternative programme attributes when 
evidence on the cost-effectiveness of the technology is not altogether compelling?  
 
Whilst NICE has identified a range of situations whereby special factors may override 
cost-effectiveness considerations alone, it remains unclear how the presence of these 
considerations may interact with the interpretation of cost-effectiveness evidence or 
how much emphasis is placed upon these by the Appraisal Committees. Several key 
issues remain unresolved: Is it possible to produce a broad framework of how equity 
concerns for a given technology should be addressed in the light of the technology’s 
cost-effectiveness profile? Can the relative importance of programme attributes be 
ranked within a hierarchy? Clearly, if the Institute’s Appraisal Committees wish to 
place a lesser weight on the cost-effectiveness of specific health technologies due to the 
presence of other special factors, it is crucial that such decisions are clearly justified 
within a consistent and transparent framework. 
 
This review highlights that NICE has multiple objectives, although specific guidance on 
how the Institute balances each of these remains unclear. The estimation of equity 
weights based on the set of relevant characteristics of the beneficiaries is beyond the 
scope of this study and is currently being undertaken elsewhere.46 Rather, the purpose 
of this study is to examine how efficiency and equity objectives are currently being 
weighted and to examine whether NICE’s decision-making approach is consistent. 
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Chapter 3  Methods 
3.1 Overview of methods 
This chapter details the methods used to examine the decision-making criteria employed 
by NICE when commissioning health care interventions. The primary research element 
of this study takes the form of a binary choice experiment. The development of the 
choice questionnaire, including the identification and selection of attributes and levels 
included in the experiment are discussed. The generation of the orthogonal sampling 
design is detailed, and issues surrounding sample sizes are highlighted. The methods for 
modelling the results of the choice questionnaire within a random effects logit 
regression model are subsequently reported. Comparisons of stated preference and 
revealed preference data relating to NICE’s decision-making criteria are also explored.  
 
3.2 Alternative methods for examining NICE’s decision-making 
criteria 
Numerous alternative approaches could be used to explore how alternative attributes 
influence NICE’s Appraisal Committees in deciding whether or not to recommend 
health care interventions for routine use on the NHS. These include reviewing current 
literature, qualitative methods, and quantitative methods. 
 
3.2.1 Literature review 
The review of current literature presented in Chapter 2 identified a diverse range of 
evidence which allows some inference concerning how NICE’s Appraisal Committees 
determine whether health technologies should be recommended or not. However, public 
comments,26;34 official guidance from NICE on the methods for Health Technology 
Appraisal,13 and published NICE guidance on the use of specific health technologies27 
do not appear to present an entirely consistent approach to making decisions on the 
basis of cost-effectiveness evidence and other considerations. At the extremes of 
Rawlins and Culyer’s adoption/rejection curve,3 the Appraisal Committees’ adoption 
decisions may be relatively easy to predict. Indeed, the Institute has afforded 
considerable effort in clarifying its decision-making approach,3-5;13 particularly in terms 
of determining two approximate inflexion points for the respective adoption and 
rejection of health technologies. The literature however highlights considerable 
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ambiguity surrounding how equity considerations and uncertainty are balanced 
alongside cost-effectiveness evidence. 
 
3.2.2 Interview-based methods 
Qualitative interviews could potentially provide further information relating to how 
NICE’s Appraisal Committees account for other considerations besides cost-
effectiveness when making commissioning decisions. Whilst interview-based methods 
are a potentially feasible approach, they are unlikely to yield full, clear and accurate 
information on how alternative programme attributes are traded off with one another in 
practice. In addition, it is unlikely that interviews would provide data which are 
appropriate for quantitative analysis. From a practical perspective, it would be 
particularly difficult to obtain direct access to Appraisal Committee members for in-
depth interviews.  
 
3.2.3 Quantitative survey of attitudes  
Attitudinal surveys represent an alternative approach to determining whether NICE’s 
Appraisal Committees take factors beside cost-effectiveness into consideration when 
deciding whether to recommend health technologies. For example, a simple structured 
questionnaire approach could be administered to each member of the Committees 
asking questions such as “Do you take the age of the patient group into consideration in 
your deliberations concerning whether to recommend health technologies?” or “Does a 
high level of parametric uncertainty influence your interpretation of the cost-
effectiveness estimate for a given technology?” The main problem with this approach is 
that it provides no information concerning the relative importance of alternative 
attributes, that is, the respondent’s preferences for individual programme attributes. 
Trade-offs between programme attributes could be indirectly addressed through the use 
of a scoring system, for example, by asking survey respondents to rate the importance 
of a given programme attribute on a scale of 1-10.  
 
3.2.4 Preference-based survey methods  
Preference data (i.e. data on the choices made by individuals) can yield information 
concerning how specific programme attributes may be traded off against one another, 
and thus provide an estimate of their relative importance. The clear benefit of 
preference data as oppose to simple attitudinal survey data is that they provide a direct, 
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rather than indirect, means of evaluating preferences. Two types of preference exist: 
revealed preferences and stated preferences. Revealed preferences refer to the 
preferences of the respondent as revealed by the choices they make, whilst stated 
preferences may be inferred from the choices that individuals say they will make within 
a controlled experiment. Interviews may be effectively used alongside stated preference 
survey methods in order to appropriately define the attributes and their levels for the 
experiment.47  
 
3.2.4.1 Revealed preference methods 
Considerable revealed preference data from NICE’s Appraisal Committees has been 
published within their guidance on the use of specific health technologies. NICE’s 
guidance reports on the use of health technologies typically present the Institute’s 
recommendations to the NHS on the use of the technology, together with details such as 
the Committee’s preferred cost-effectiveness estimate(s), the expected degree of clinical 
benefit, and any additional considerations that were considered important during the 
appraisal. NICE’s guidance reports represent a potentially rich, reliable and valid data 
source, however, the use of revealed preference data to estimate the relative importance 
of individual programme attributes is subject to some important problems: 
(1) The factors detailed within guidance documents may not fully reflect all of the 
individual factors considered by the Committee at the time of the appraisal. 
(2) The aggregation of all revealed preference data from guidance reports since the 
inception of NICE’s Appraisal Committees does not allow for organisational 
learning through experience, and the evolution of the Committee’s decision-
making criteria over time (although this could be incorporated into a statistical 
choice model). 
(3) The range of factors considered by the Committees is not consistently reported 
within NICE technology guidance reports. For example, Devlin and Parkin’s 
revealed preference analysis (See Section 2.5.4) was restricted to only four basic 
attributes, for which full information was reported for only 33 of 51 decisions. 23 
Consequently, the attributes included in the revealed preference model, and the 
number of observations (decisions) available, were constrained by the limited 
information reported with NICE guidance reports. As equity issues are not 
consistently reported within guidance documents, Devlin and Parkin’s analysis 
was restricted only to efficiency-related attributes.  
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3.2.4.2 Stated preference methods 
The evaluation of stated preference data using conjoint analysis is typically more 
flexible than its revealed preference counterpart due to the adoption of a controlled 
decision-making environment.48 Stated preference discrete choice methods allow for the 
estimation of the relative importance of different attributes (that is characteristics or 
features) in the provision of a good or service.49 Stated preference techniques have been 
commonly applied within market research, the environmental sector, the transport 
sector and health care.47;49-60  
 
The main principle which underpins stated preference techniques is the assumption that 
an individual’s preferences are reflected in their respective utility functions. The 
establishment of a controlled environment and the use of an experimental design enable 
the utility associated with alternative options to be estimated. Stated preference data 
may be collected using a simple survey design, whereby potential respondents are 
presented with a questionnaire consisting of a series of discrete or binary choices. For 
each choice scenario, individuals are asked to indicate their preferred option. Analysis 
of the response data using statistical models allows for the delineation of the total utility 
function such that the statistical contribution of each attribute to the explanation of a 
choice response, and hence the impact of the attribute on total utility, can be estimated 
thereby indicating its relative importance.48  
 
Each of the respondent’s choice can be seen as a comparison of two indirect utility 
functions and can be analysed within the framework of Random Utility Theory (RUT).49 
Expected Utility Theory61 suggests that the respondent will choose scenario A over 
scenario B if the expected utility associated with Scenario B is greater than the expected 
utility associated with Scenario A. 
 
)()( AUBU >          (3.1)  
 
The probability that an individual chooses scenario A is a function of the difference in 
utility between the two scenarios {U(B)-U(A)}. The analysis of discrete or binary choice 
data within the framework of RUT requires the inclusion of an error term in the utility 
function to reflect the unobservable and immeasurable factors in the respondent’s utility 
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function. This error term is necessary due to imperfect knowledge concerning the exact 
form of the utility function and the researcher’s inability to recognise and empirically 
measure all factors which influence a respondent’s choice.47 Consequently, an individual 
will choose Scenario B over Scenario A if the measurable component of utility (VB) plus 
the unobservable component of utility associated with scenario B (EB) is greater than the 
measurable component of utility (VA) plus the unobservable component of utility 
associated with scenario A (EA).47 
 
)E(V)E(VBChoose AABB +>+ if        (3.2) 
 
The measurable components of utility for each scenario (VB and VA) can be estimated 
directly from the response data. The unobservable utility components of utility (EB and 
EA) concerns the effect of those variables which are not included in the choice experiment 
but which are taken into account by the respondent in making actual choices (ea), and the 
errors specific to the conjoint analysis exercise (ec).47 
  
eceaEcomponentutilityleUnobservab +=        (3.3) 
 
Empirical evidence suggests stated preference surveys can produce data which are 
consistent with RUT, from which econometric models can be estimated which are 
indistinguishable from their revealed preference counterparts.48 One of the key benefits 
of stated preference techniques is that they may be more flexible than revealed 
preference data, as the use of a controlled environment allows for the utility function for 
respondents to be mapped over a large number of scenarios which have not yet arisen. 
In addition, stated preference techniques can yield multiple observations for each 
respondent at each observation point.48  
 
3.3 Study subjects – The NICE Appraisal Committees 
The three NICE Appraisal Committees were identified as the relevant group of 
participants for the study, as these Committees make recommendations concerning the 
use of specific health technologies on the NHS. A key benefit of eliciting stated 
preference data from individual members of the Appraisal Committees is that response 
data reflect the views of the individual rather than the consensus view of the Committee 
as a whole; given the multidisciplinary background of the Committee members, this 
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could lead to important variations in the responses elicited. The main problem 
associated with eliciting responses from the Appraisal Committees concerns the limited 
sample size (81 members); previous simulation work suggests that more than 150 
respondents may be necessary to protect against biased parameter estimates (Personal 
communication, Dr Terry Flynn, Medical Research Council Health Services Research 
Collaboration, Bristol). Inevitably, the experiment is likely to be underpowered, thus 
the results should be considered exploratory. 
 
Two further important problems relating to the use of a stated preference approach to 
determine NICE’s decision-making criteria should be highlighted a priori. A generic 
problem associated with stated preference techniques is that individuals do not always 
do what they say they will do in reality. Appraisal Committee members may state that 
they would recommend a technology with a given set of programme attributes within a 
controlled experiment, but may not make the same decision for a technology with 
similar characteristics in reality. Secondly, whilst the elicitation of individual preference 
data from a group of decision-makers may highlight variations in preferences between 
the individual Committee members, informational influences and normative influences 
on group decision-making,62 such as the differential influence of individual Committee 
members on final recommendations, will not be captured. 
 
3.4 Methods for the design and analysis of a stated preference 
binary choice experiment to explore NICE’s decision-making criteria 
3.4.1 Identification of key attributes  
The scope of the analysis is crucial to its reliability and validity, as the attributes 
identified for inclusion in the experiment indirectly determine the quality of the results 
obtained.47 Numerous programme attributes may be explicitly considered by health 
service decision-makers when commissioning health interventions, each of which could 
be included within a stated choice experiment. Furthermore, it is possible to describe 
the levels associated with many attributes in several different ways. Table 1 presents a 
non-exhaustive list of the types of attributes which may influence health care 
commissioning decisions, as identified within Chapter 2. 
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Table 1  Potential attributes which may influence health care commissioning 
decisions 
Attribute Attribute description Example unit of measurement 
1) Clinical 
effectiveness  
Incremental clinical benefits resulting 
from the technology under 
consideration compared to the current 
standard treatment.  
Life years gained 
QALYs gained 
Disease-specific outcomes  
2) Nature of effect Whether the intervention is life-saving 
and/or improves HRQoL 
Life-saving/HRQoL-gaining 
3) Cost-
effectiveness/  
cost-utility 
Central estimate of incremental cost-
effectiveness/cost-utility. Calculated as 
the incremental cost divided by the 
incremental benefits gained. 
Cost per life year gained 
Cost per QALY gained 
Cost per event avoided etc. 
4) Expected net 
benefit 
Additional benefits associated with the 
technology under consideration valued 
in monetary terms after adjusting for 
cost consequences. 
Pounds sterling 
5) Baseline 
HRQoL 
Pre-treatment health utility score.  Index ranging from 0 (“dead”) 
to 1.0 (“perfect health”). 
Negative scores may be used to 
represent health states worse 
than death, depending on Health 
Status Measure (HSM) used. 
6) Cost-
effectiveness/ 
decision 
uncertainty 
Described by illustrative cost-
effectiveness plane, cost-effectiveness 
acceptability curve, probability of 
being dominated, confidence intervals 
for cost-effectiveness ratio 
Incremental costs and 
incremental life years/QALYs 
gained 
Cost per QALY range or 
confidence intervals 
Probability of being dominated 
Probability of being optimal at a 
given willingness to pay 
threshold 
7) Age Age of target population for the 
technology under consideration 
Years/Years of life remaining 
8) Responsibility 
for condition 
Whether the individual is in some way 
responsible for their disease or 
condition (e.g. lung cancer resulting 
from smoking) 
Patient is partially responsible 
for condition/Patient is not 
responsible for condition 
9) Availability of 
other therapies 
Whether effective alternative therapies 
are available for the treatment of the 
disease or whether the current standard 
treatment is best supportive care 
Yes/No 
10) Burden of 
disease 
Prevalence of disease or condition Number of patients 
11) Affordability  Absolute/incremental annual cost to the 
NHS associated with providing the 
technology under consideration  
Pounds sterling 
12) Cost per 
patient treated 
Absolute/incremental annual 
direct/indirect cost of providing the 
technology under consideration for an 
individual patient 
Pounds sterling 
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Clearly, numerous alternative study designs are possible, depending on how many 
attributes are included within the experiment, how the attributes are described, and how 
many levels are used to describe each attribute. It should be noted from the outset that 
design and sampling issues for choice experiments should be considered in concert: 
good design will not compensate for inadequate sampling and vice versa.48 Ideally, all 
independent attributes detailed in Table 1 would be included in the study, each of which 
would be described over a large number of levels. However, the number of attributes 
included within this experiment was restricted by a number of practical considerations.  
(1) Cognitive complexity. Information Processing Theory63 suggests that people can 
only process up to around seven pieces of information (plus or minus around 
two pieces of information). Owing to the potential cognitive complexity of the 
choice experiment, it was decided that no more than five attributes should be 
included within each choice scenario. 
(2) Task burden. It was anticipated a priori that the increasing burden of the task, 
particularly in terms of time required, would reduce the response rate for the 
survey. The presentation of a large number of choice scenarios within each 
questionnaire may cause respondents to become bored and lead to respondent 
fatigue biases which may undermine the validity of the study. A full factorial 
design across the five attributes would require 108 scenarios, which is clearly 
infeasible (See Section 3.5). The study group decided that no more than 20 
choice scenarios should be included within the experiment.  
(3) Independence of attributes. In order to allow for the estimation of the utility 
associated with individual attributes, all attributes included within the utility 
model must be independent of one another, thus avoiding problems of 
multicollinearity. Interactions were excluded from the analysis, as their inclusion 
would increase the burden of the task. It should be noted that several of the 
attributes are simply alternative descriptions of the same dimension (for example 
expected net benefit and cost-effectiveness are closely related concepts), and 
some dimensions incorporate information on other dimensions (for example, 
age, the clinical effectiveness of the intervention, and the nature of the treatment 
effect should be captured within the cost per QALY estimate). Consequently, the 
number of independent programme attributes is reduced considerably. 
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The initial set of attributes and levels to be included in the analysis were selected by the 
study group (See Acknowledgements) using official NICE documentation describing 
the factors considered by the Appraisal Committees,13 and through correspondence with 
a representative from NICE (Dr Carole Longson, Appraisals Programme Director, 
NICE, London). The attributes included in the experiment are detailed in Table 2.  
 
Table 2 List of attributes and descriptions included in the choice experiment 
Attribute Attribute description 
1) Incremental cost per 
QALY gained 
The central estimate of cost-effectiveness for the intervention as 
compared to the current standard treatment. This is calculated as the 
additional cost of the intervention compared to the current standard 
treatment divided by the additional benefits of the intervention 
compared to the current standard treatment. 
2) Uncertainty The degree of uncertainty surrounding incremental costs and effects.  
3) Age The mean age of the population who will benefit from the 
intervention. 
4) Baseline HRQoL The mean health-related quality of life score of patients prior to 
receiving the intervention, whereby “1” represents a state of perfect 
health and “0” represents dead.  
5) Availability of other 
therapies  
Whether alternative effective therapies are available to manage the 
condition or not.  
 
3.4.2 Discrete versus binary choices 
For this particular experiment, the standard pairwise discrete choice design is 
inappropriate due to the inclusion of the cost-effectiveness attribute. The description of 
incremental cost-effectiveness using the pairwise discrete choice model means that the 
respondent is actually asked to compare four technologies: Intervention A, Intervention 
B as well as the relevant comparator for Intervention A and the relevant comparator for 
Intervention B. Not only would such an approach be cognitively difficult, but 
comparing cost-effectiveness ratios between interventions with different baselines is 
theoretically flawed. For example, consider Intervention A, which costs an additional 
£5,000 and provides an extra 2 QALYs compared to its comparator, and Intervention B 
which costs an additional £20,000 and provides an extra 4 QALYs over its comparator. 
On the basis of cost-effectiveness information alone, one would prefer Intervention A 
(A=£2,500 per QALY gained, B=£5,000 per QALY gained). However, if the value of 
each QALY is greater than £7,500, intervention B may be considered preferable on the 
basis of incremental net benefit. The net benefit approach would avoid the lack of 
sensitivity of the cost per QALY ratio, however, the Appraisals Committees do not 
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work in these terms (Personal communication, Dr Carole Longson, Appraisals 
Programme Director, NICE, London).  
 
Perhaps more importantly, whilst the Institute’s Appraisal Committees may draw from 
their experience during previous technology appraisals, the traditional discrete model is 
not representative of the Institute’s “case by case” decision-making approach.3 
Consequently, the standard pairwise discrete choice model would have poor face 
validity, and would not reflect the way in which the Appraisal Committees actually 
make decisions in practice. In order to resolve these problems, a binary response 
scenario approach was adopted. Using the binary response format, Committee members 
were presented with a series of scenarios which presented information relating to the 
five attributes, and were asked to indicate whether they would recommend the 
intervention under consideration or not (See Appendix 1). 
 
3.4.3 Identification of attribute levels 
The levels assigned to each attribute, that is the values that each attribute may take, 
must be plausible to respondents and realisable in practice.49 In addition, the levels 
assigned to each attribute should be capable of being traded off against one another; if 
changes in the levels of an individual attribute are considered by the respondent to be 
too small to be of importance, the attribute is likely to be ignored.49 Whilst assigning a 
larger number of levels to each attribute would provide additional information, in 
practice, the desire for more information must be traded off with the complexity that 
arises from the inclusion of a large number of attributes and levels.47 The levels 
assigned to each attribute within this choice experiment were initially selected by the 
study group with the input of Dr Carole Longson (Appraisals Programme Director, 
NICE, London).  
 
In order to assess the validity of the questionnaire and to determine whether the selected 
attributes and levels were capable of being traded off against one another within a stated 
preference framework, a limited sample pilot study was undertaken within the Health 
Economics and Decision Science (HEDS) Section within the School of Health and 
Related Research (ScHARR). The HEDS Section was selected as the study population 
for the pilot, as the majority of staff members are familiar with the concepts commonly 
faced by NICE’s Appraisal Committees. Two minor adjustments were made to the 
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levels assigned to the attributes based on the feedback from the pilot study. Firstly, the 
cost per QALY gained levels were changed to better reflect Rawlins and Culyer’s3 
adoption/rejection curve (previously described as £20,000, £30,000 and £40,000 per 
QALY gained). Secondly, the description of uncertainty was changed due to problems 
in interpreting this attribute, and due to the presence of multicollinearity between the 
incremental cost per QALY gained attribute and the uncertainty attribute (previously 
described as the probability of being optimal at £30,000 per QALY gained, as 
represented by a single point on a CEAcc). The final set of attributes and levels used 
within the main study is detailed in Table 3.  
 
Table 3  Attributes and levels included in the choice experiment 
Attribute Levels included 
1) Incremental cost per QALY gained 0) £15,000 per QALY gained 
1) £25,000 per QALY gained 
2) £35,000 per QALY gained 
2) Uncertainty 0) Low degree of uncertainty 
1) High degree of uncertainty  
3) Age 0) Children (<18 years) 
1) Working (18-64 years) 
2) Retired (>64 years) 
4) Baseline HRQoL 0) 0.25 
1) 0.50 
2) 0.75 
5) Are other therapies available? 0) No  
1) Yes 
 
As noted in Section 3.4.1, the selection of attributes and levels included within the 
choice experiment are central to its validity and reliability. The selection of levels used 
to describe each attribute therefore warrants further justification. It should be noted that 
the choice questionnaire included a brief key which described the meaning of each 
attribute and outlined their possible levels (See Appendix 1).  
  
3.4.3.1 Incremental cost per QALY gained 
The inclusion of the cost-effectiveness attribute was led by the objective of the study 
(See Section 1.2). Three levels were assigned to the cost-effectiveness attribute: (0) 
£15,000, (1) £25,000 and (2) £35,000 per QALY gained. These three levels were 
selected in order to broadly reflect the inflexion points for adoption and rejection 
suggested by Rawlins and Culyer.3  
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3.4.3.2 Uncertainty 
The decisions made by NICE’s Appraisal Committees may be influenced by the degree 
of uncertainty surrounding the incremental costs and effects of a health technology, and 
the likelihood that the technology under consideration is optimal compared to the 
current standard treatment. However, describing the level of uncertainty surrounding 
incremental costs and benefits without introducing correlations with the cost-
effectiveness attribute is problematic. Initially, it was intended that the uncertainty 
attribute would be described as a single point on a CEAcc, i.e. the probability of being 
optimal at £30,000 per QALY gained. However, this approach would imply the 
existence of a fixed cost-effectiveness threshold, and leads to unrealistic combinations 
of the cost-effectiveness and uncertainty attribute levels, e.g. mean cost-effectiveness of 
£15,000 per QALY gained combined with a 30% probability of having a cost-
effectiveness that is better than £20,000 per QALY gained. As noted in Section 3.4.3, 
this problem was highlighted through feedback from the pilot study.  
 
Alternatively, using a range of costs and benefits (e.g. +/-£10,000 per QALY gained) is 
problematic as the cost per QALY scale is not fully continuous; as incremental costs 
and effects cross the axes of the cost-effectiveness plane, the resulting cost-
effectiveness ratio tends towards plus infinity or minus infinity. A range of uncertainty 
around the expected incremental net benefit would be more appropriate, however, as 
noted in Section 3.4.2, the Appraisal Committee does not directly make decisions using 
this metric (although they do consider the results of probabilistic sensitivity analyses 
presented using acceptability curves). 
 
As a result of these practical problems, a more subjective approach was adopted. Two 
levels were assigned to the uncertainty attribute: (0) low level of uncertainty, and (1) 
high level of uncertainty. The main benefit of this approach is that the uncertainty and 
cost-effectiveness attributes remain independent. However, the limitation of describing 
the uncertainty surrounding incremental costs and effects in this manner is that the 
interpretation of the degree of uncertainty may differ between respondents e.g. one 
respondent may interpret a high degree of uncertainty as the therapy being potentially 
dominated, whilst another respondent may not. Figure 3 shows the description of the 
two levels of uncertainty used within the experiment; this diagram was displayed in the 
attribute key presented at the beginning of the choice questionnaire (See Appendix 1). 
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Figure 3          Description of uncertainty used in choice questionnaire 
 
3.4.3.3 Age 
The Institute’s draft consultation document on social value judgements suggests that 
whilst health should not be valued more highly for some age groups rather than others, 
where age is an indicator of benefit or risk, age discrimination is appropriate.5;64 Whilst 
the element of age is incorporated in the number of QALYs gained, and as such directly 
affects the cost-effectiveness of an intervention, the age of the patient population may 
be given additional equity weight; it is this potential additional weighting that this 
attribute was intended to capture. For the purpose of simplicity, three levels were 
assigned to this attribute: (0) children under 18 years of age, (1) working adults between 
18-64 years of age, and (2) retired adults over 64 years of age. 
 
3.4.3.4 Baseline HRQoL 
The baseline HRQoL of the population who would receive the intervention was taken to 
represent a proxy for clinical need. This attribute describes the baseline health status of 
the target population without treatment with the therapy under consideration, as 
described by a health utility index scale ranging from 0 (“dead”) to 1 (“perfect health). 
Three levels were assigned to describe this attribute: (0) 0.25, (1) 0.50, and (2) 0.75; 
these levels were intended to broadly capture patients with high, moderate and low 
HRQoL respectively. 
 
3.4.3.5 Availability of other therapies 
The degree to which the availability of established effective therapies to manage or treat 
diseases influences the Appraisal Committees’ decision-making is not clear within the 
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literature. Needless to say however, the Institute does undertake appraisals of 
technologies used to treat conditions whereby the current standard treatment is best 
supportive care (for example, the use of disease-modifying therapies for the 
management of multiple sclerosis). The relative importance of other programme 
attributes may be dependent on whether effective therapies are established for the 
treatment of the disease under consideration. Two levels were assigned to this attribute: 
(0) no other effective therapies are available, thus the comparator is best supportive 
care, and (1) other therapies are available. 
 
It should be noted that the inclusion of the “other therapies” attribute essentially 
changes the baseline option if respondents do not recommend the intervention under 
consideration, therefore the baseline choice is different for scenarios in which other 
therapies are available and scenarios in which the comparator is best supportive care 
(Personal communication, Dr Terry Flynn, Medical Research Council Health Services 
Research Collaboration, Bristol). In order to explore the impact of this potential 
confounding, a separate regression model was estimated for those scenarios in which 
other therapies were available, and the results of this analysis were then compared to the 
results of the main analysis. 
 
3.5 Design of experiments 
As noted in Section 3.4.1, the design of the experiment was considered alongside 
decisions concerning the number of attributes and levels to be included in the choice 
experiment. Whilst a full factorial design (33 x 22=108 scenarios) would allow for more 
precise estimates of utility through the inclusion of all possible effects, it is unlikely that 
any of the Appraisal Committee members would have responded to such a lengthy 
questionnaire. Instead, a fractional factorial main effects design (excluding interactions) 
was sampled from the complete factorial. It should be noted that currently there remains 
no consensus on the number of profiles that respondents need to complete to ensure 
reliable and valid parameter estimates. Louviere et al48 note that many experiments that 
have implemented 32 or more profiles successfully. However, it was felt that presenting 
potential respondents with more than 20 scenarios would dramatically reduce response 
rates. Consequently, 18 scenarios were sampled using an orthogonal main effects only 
design. ORTHOPLAN®, an orthogonal random sampling routine within the SPSS® 
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statistical program (SPSS Inc, Illnois), was used to generate the final set of 18 choice 
scenarios.  
 
The sampling design used within the choice questionnaire is presented in Table 4. It 
should be noted that given the use of three three-level attributes and two two-level 
attributes, it was not possible to generate a fractional factorial design which maintained 
both balance and orthogonality (Personal communication, Professor David Grey, 
Department of Probability and Statistics, University of Sheffield). As a result, it was 
decided that orthogonality should be preserved at the cost of balance. The implication of 
this trade-off is that the magnitude of standard errors estimated from the regression 
model would differ between attribute levels (Personal communication, Dr Terry Flynn, 
Medical Research Council Health Services Research Collaboration, Bristol).  
 
The same set of scenarios was presented in each choice questionnaire. Whilst there may 
be some potential benefit in randomly sampling a set of possible choices for each 
potential participant, as more choices could be presented, this approach would have 
assumed homogeneity of preferences between Appraisal Committee members, and as 
such may have biased the results obtained from such a small sample.  
 
Table 4  Main effects only design codes for binary choice experiment  
Scenario  
Incremental 
cost per QALY 
gained 
Degree of 
uncertainty around 
mean cost-
effectiveness 
Age of 
target 
population 
Baseline 
HRQoL 
Are other 
therapies 
available? 
1 1 0 1 2 1 
2 0 1 1 1 1 
3 1 1 1 1 0 
4 2 1 1 2 1 
5 2 1 0 2 1 
6 0 1 2 2 0 
7 0 0 2 1 1 
8 1 1 0 1 0 
9 1 0 0 0 1 
10 1 1 2 0 1 
11 0 1 1 0 1 
12 1 1 2 2 1 
13 0 0 0 2 0 
14 2 0 1 0 0 
15 0 1 0 0 1 
16 2 0 2 1 1 
17 2 1 2 0 0 
18 2 1 0 1 1 
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Table 5 shows the corresponding quantitative and qualitative attribute level descriptions 
for the choice scenarios included in the questionnaire. 
 
Table 5          Main effects only choice scenarios for binary choice experiment 
Scenario  
Incremental 
cost per QALY 
gained 
Degree of 
uncertainty around 
mean cost-
effectiveness 
Age of 
target 
population 
Baseline 
HRQoL 
Are other 
therapies 
available? 
1 £25,000 Low Working 0.75 Yes 
2 £15,000 High Working 0.50 Yes 
3 £25,000 High Working 0.50 No 
4 £35,000 High Working 0.75 Yes 
5 £35,000 High Children 0.75 Yes 
6 £15,000 High Retired 0.75 No 
7 £15,000 Low Retired 0.50 Yes 
8 £25,000 High Children 0.50 No 
9 £25,000 Low Children 0.25 Yes 
10 £25,000 High Retired 0.25 Yes 
11 £15,000 High Working 0.25 Yes 
12 £25,000 High Retired 0.75 Yes 
13 £15,000 Low Children 0.75 No 
14 £35,000 Low Working 0.25 No 
15 £15,000 High Children 0.25 Yes 
16 £35,000 Low Retired 0.50 Yes 
17 £35,000 High Retired 0.25 No 
18 £35,000 High Children 0.50 Yes 
 
3.6 Questionnaire format and administration 
The complete questionnaire is presented in Appendix 1. Each sampled choice scenario 
was presented as an individual table of characteristics, analogous to a simplified version 
of the range of evidence considered during each technology appraisal. For each 
scenario, participants were asked to indicate whether they would be likely to 
recommend the intervention or not. A key describing each of the attributes and the 
levels was presented at the beginning of the questionnaire. An information sheet 
detailing the purpose of the study, instructions for participants, contact details of the 
study group, and the proposed dissemination strategy was also presented at the 
beginning of the questionnaire (See Appendix 1). Whilst it would have been useful to 
collect demographic information on study respondents, the study group felt that 
absolute anonymity would maximise response rates.  
 
The objectives, methods of the study and the requirements of study participants were 
briefly presented to each of the three Appraisal Committees at the end of routine 
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Appraisal Committee meetings in May and June 2005 by Professor David Barnett 
(Chair of NICE Appraisals Committees, National Institute for Health and Clinical 
Excellence, London) on behalf of the study group (See Appendix 2).  
 
3.7 Statistical analysis 
3.7.1 Assessment of logical consistency  
The internal validity of the binary response data elicited from Appraisal Committee 
members was explored using a test of logical consistency. The logical consistency of 
the response data was tested by comparing individual-level responses between pairs of 
scenarios in which all but one of the attribute levels were identical. For example, choice 
scenarios 7 and 16 differ (See Tables 4 and 5) only in terms of the cost per QALY 
attribute level (£15,000 per QALY gained vs. £35,000 per QALY gained for scenarios 7 
and 16 respectively). Logically, an individual who recommends the intervention under 
consideration described by scenario 16 should also recommend the intervention under 
consideration described by scenario 7, as it describes the same population of patients 
but the intervention has a lower incremental cost-effectiveness ratio. Table 6 shows the 
scenarios comparisons used to test the logical consistency of the response data.  
 
Table 6  Scenario comparisons used for tests of logical consistency* 
Scenario 
comparison 
Different attribute 
level Identical attribute levels Logical consistency rule 
Scenario 2 
versus 
Scenario 11 
Scenario 2)  
HRQoL=0.50 
Scenario 11) 
HRQoL=0.25 
£15,000 per QALY gained 
High level of uncertainty 
Working adults 
Other therapies available 
Respondents who recommend 
the intervention for scenario 2 
should recommend the 
intervention for scenario 11 
Scenario 5 
versus 
Scenario 18 
Scenario 5)  
HRQoL=0.75 
Scenario 18)  
HRQoL=0.50 
£35,000 per QALY gained 
High level of uncertainty 
Children 
Other therapies available 
Respondents who recommend 
the intervention for scenario 5 
should recommend the 
intervention for scenario 18 
Scenario 10 
versus 
Scenario 12 
Scenario 10)  
HRQoL=0.25 
Scenario 12)  
HRQoL=0.75 
£25,000 per QALY gained 
High level of uncertainty 
Retired adults 
Other therapies available 
Respondents who recommend 
the intervention for scenario 
12 should recommend the 
intervention for scenario 12 
Scenario 7 
versus 
Scenario 16 
Scenario 7)  
£15,000 per 
QALY gained  
Scenario 16)  
£35,000 per 
QALY gained  
Low level of uncertainty 
Retired adults 
HRQoL=0.50 
Other therapies available 
Respondents who recommend 
the intervention for scenario 
16 should recommend the 
intervention for scenario 7 
*Three pairs of scenarios differed only in terms of age, but were excluded from the internal consistency 
assessment due to absence of a logical order of preference 
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3.7.2 Logit regression modelling 
The use of a simple binary response format means that a simple binary logit model 
(BLM) is appropriate. The mathematical formulation for the logit model has been 
previously detailed by Louviere et al,48 and is presented below for purposes of 
transparency (equations 3.4–3.8). The functional form of the binary logit model may be 
expressed as:  
 
)]exp()/[exp()exp()| noyesyes VVVyes,noP(yes +=  (3.4) 
 
where Vs are the systematic utility components. The value of Vno can be set to zero with 
no loss of generality, which gives: 
 
1)/[exp()exp(),|( += yesyes VVnoyesyesP  (3.5) 
 
Through considering the odds of responding “yes”, which in this case corresponds to 
“recommend intervention under consideration over the current treatment”, relative to 
“no”, which corresponds to “do not recommend intervention under consideration over 
the current treatment”, this gives: 
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If the exp(Vno) is specified as 1, taking natural logarithms of both sides gives:  
 
yese V
noyesnoP
noyesyesP
=
ú
ú
ú
û
ù
ê
ê
ê
ë
é
),|(
),|(
log   (3.7) 
 
When Vyes is specified as a linear-in-the-parameters expression, this gives: 
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where βk is a vector of taste weights associated with K attribute vectors, Xk; and αm is a 
vector of effects associated with M individual characteristics interacted with either the 
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“yes” intercept or elements of the X vector, Zm.48 A simple additive logit regression 
function, which gives the odds of a “yes” response relative to a “no” response, can thus 
be expressed as: 
 
eXXX
noyesno
noyesyesLog LL +++= bbbb .......22110
,|
),|(  (3.9) 
where X1,X2…XL   =  specified levels of L attributes included in the model 
β0,  β 1, β 2….. βL  =   coefficients which are estimated from the regression  
    equation 
e                      =  error term which is included to allow for factors that  
influence utility which have not been controlled for in the 
model 
The corresponding utility function was estimated by transforming the logit function as 
shown below. 
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All statistical analysis was undertaken using STATA® statistical software (STATA 
Corporation, Texas). Logit regression analysis was undertaken whereby “Response” was 
the dependent variable and the five attributes were the independent variables (See Table 
7). Robust standard errors were calculated by allowing for clustering within individual 
responses. Both log odds ratios and standardised odds ratios were calculated for β 
coefficients. For each of the attributes, the base level for the regression analysis was 
defined as the level which is most likely to lead to a positive recommendation for the 
therapy under consideration, thus the resulting odds ratios describe the reduction in the 
odds of adoption for increasingly less preferable attribute levels relative to the base level. 
Categorical variables were used to describe the levels for each of the five attributes, as the 
cost per QALY scale is not continuous (See Section 3.4.3.2), and the baseline HRQoL 
attribute was intended to describe three groups of individuals (healthy, sick, very sick) 
rather than a continuous scale.  
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Table 7 Description of variables included in the logit regression model 
Variable Variable type Coded attribute levels* 
Response Binary 1=recommend intervention under 
consideration 
0=do not recommend intervention under 
consideration 
Cost per QALY Categorical 0=£15,000 per QALY gained 
1=£25,000 per QALY gained 
2=£35,000 per QALY gained 
Uncertainty Categorical 0=low 
1=high 
Age Categorical 0=Children  
1=Working 
2=Retired 
Baseline HRQoL Categorical 0=0.25 
1=0.50 
2=0.75 
Other Therapies Categorical 0=no other therapies available 
1=other therapies available 
*Attribute level 0 held as base value for logit regression  
 
The explanatory power of the model was assessed by comparing the observed adoption 
probabilities from the empirical response data for each scenario with the expected 
probability of adoption from the logit regression model.  
 
It was intended that marginal rates of substitution, that is, the rate at which individuals are 
willing to give up one attribute in order to receive another, would be calculated by 
dividing the logit coefficients describing the change in the level for one attribute by the 
change in the level for the incremental cost-effectiveness ratio. However, as the cost per 
QALY scale is not continuous, the resulting marginal rates of substitution would be 
misleading and therefore are not presented here. Despite these problems in estimating 
marginal rates of substitution, the relative importance of the alternative attributes may still 
be observed by examining the coefficients estimated within the regression model. 
 
3.7.3 Assessing the external validity of the stated preference model: 
comparison against revealed preferences 
Clearly, the utility of the model is largely dependent on its criterion validity, that is, the 
model’s ability to predict the Appraisal Committees’ actual recommendations 
concerning the use of specific health technologies. In order to test the predictive ability 
of the model, choice scenarios were generated based upon published guidance on the 
use of seven technologies (or groups of technologies) recently appraised by NICE, as 
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detailed in Table 8. Information relating to incremental cost-effectiveness, uncertainty, 
age, baseline HRQoL, and the availability of other therapies was extracted and inputted 
into the regression model. Where data were unavailable, evidence from the 
corresponding Assessment Group reports were used instead. The estimated probability 
that an individual technology would be recommended was then compared against the 
recommendation made by the Institute. As the model estimates odds ratios or 
probabilities of acceptance rather than binary “yes” or ”no” outcomes, it was assumed 
that a predicted probability greater than 0.5 represents a “yes”, whilst a predicted 
probability less than 0.5 represents a “no.” 
 
Table 8  Case study appraisals used to assess criterion validity 
Appraisal 
number Technology appraisal Date published 
80 Clopidogrel in the treatment of non-ST-segment-elevation 
acute coronary syndrome 
July 2004 
41 Routine antenatal anti-D prophylaxis for RhD-negative 
women 
May 2002 
72 Anakinra for rheumatoid arthritis November 2003 
65 Rituximab for aggressive non-Hodgkin’s lymphoma September 2003 
69 Liquid-based cytology for cervical screening October 2003 
32 Beta interferon and glatiramer acetate for the treatment of 
Multiple Sclerosis 
January 2002 
14 Ribavirin and interferon alpha for Hepatitis C October 2003 
 
Two limitations of the assessment of criterion validity should be noted: 
(1) The stated preference model uses five categorical variables to describe the 
attribute levels, thus dummy variables are used to describe whether the selected 
attribute level is present or not. In order to replicate revealed preference 
scenarios for use in the stated preference model, it was necessary to assume each 
actual attribute level took the value of its nearest equivalent in the choice model, 
e.g. an actual cost-effectiveness ratio of £28,700 would be inputted as “level 1” 
(£25,000 per QALY gained) within the choice model.  
(2) Complete information on all attributes was not always available within either the 
NICE guidance reports or the corresponding Technology Assessment Reports. 
For example, baseline HRQoL and the degree of uncertainty surrounding 
incremental costs and effects were not consistently reported within the NICE 
guidance documents. Where quality of life evidence was not available within 
these reports, utility scores were obtained from the Harvard Catalogue of 
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Preference Scores.65 Where available, the degree of economic uncertainty 
(simply categorised in terms of high or low uncertainty) was assumed from 
further investigation of uncertainty analysis presented within the Technology 
Assessment Reports. Where multiple cost-effectiveness ratios were reported, the 
mean value was assumed.  
 
The necessary use of these assumptions means that the assessment of criterion validity 
should be considered to be exploratory. 
 
3.8 Research ethics  
Ethical approval for this study was obtained from the Sheffield University Research 
Ethics Committee (UREC). The letter of ethical approval is presented in Appendix 3. 
Permission to distribute the choice questionnaire was kindly granted by Professor David 
Barnett (Chair of Appraisal Committee, NICE, London), Professor Andrew Stevens 
(Chair of Appraisal Committee, NICE, London), and Dr Carole Longson (Dr Carole 
Longson, Appraisals Programme Director, NICE, London).  
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Chapter 4  Results 
4.1 Overview of results 
This chapter details the results of the binary choice experiment, beginning with an 
assessment of the internal validity of the elicited response data. The results of the logit 
regression analysis are presented and discussed. Estimated odds ratios for the adoption 
of technologies obtained from the regression analysis are compared to the empirical 
response data to demonstrate the explanatory power of the model. Sensitivity analyses 
are presented using probit regression analysis, and separate results for different 
comparators are reported and their validity discussed. The external validity of the logit 
regression model is explored by testing its ability to predict adoption/rejection decisions 
made by NICE’s Appraisal Committees during recent technology appraisals. Finally, 
the limitations of the model and analysis are discussed. 
 
4.2 Empirical response data  
4.2.1 Response rate 
A total of 37 responses were obtained from the three NICE Appraisal Committees 
(approximately 46%), which corresponded to 664 choice responses. Whilst the number 
of responses obtained represents a usable sample of the Committee members, further 
responses could have helped to provide a more representative sample and additional 
statistical power.  
 
4.2.2 Empirical response data 
Table 9 presents a summary of the response data obtained from members of the NICE 
Appraisal Committees.  
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Table 9  Summary of response data  
Attributes Adopt the intervention? 
Scenario Cost per 
QALY 
gained 
Uncertainty Age Baseline HRQoL 
Other 
therapies? Yes No 
P(adopt) 
1 £25,000 Low Working 0.75 Yes 24 13 0.65 
2* £15,000 High Working 0.50 Yes 30 6 0.83 
3* £25,000 High Working 0.50 No 27 9 0.75 
4 £35,000 High Working 0.75 Yes 0 37 0.00 
5 £35,000 High Children 0.75 Yes 0 37 0.00 
6 £15,000 High Retired 0.75 No 33 4 0.89 
7 £15,000 Low Retired 0.50 Yes 35 2 0.95 
8 £25,000 High Children 0.50 No 29 8 0.78 
9 £25,000 Low Children 0.25 Yes 25 12 0.68 
10 £25,000 High Retired 0.25 Yes 15 22 0.41 
11 £15,000 High Working 0.25 Yes 32 5 0.86 
12 £25,000 High Retired 0.75 Yes 10 27 0.27 
13 £15,000 Low Children 0.75 No 37 0 1.00 
14 £35,000 Low Working 0.25 No 19 18 0.51 
15 £15,000 High Children 0.25 Yes 29 8 0.78 
16 £35,000 Low Retired 0.50 Yes 6 31 0.16 
17 £35,000 High Retired 0.25 No 13 24 0.35 
18 £35,000 High Children 0.50 Yes 5 32 0.14 
*One respondent did not state a preference for scenarios 2 and 3 
 
Table 9 demonstrates that for some of the scenarios, the responses were entirely 
consistent across all participating Appraisal Committee members. For example, all 
respondents stated that they would not recommend the interventions under 
consideration described by scenario 4 and scenario 5, whereby the incremental cost per 
QALY gained appears to be unfavourable and incremental costs and effects are highly 
uncertain. Similarly, all study respondents stated that they would recommend the 
intervention under consideration described by scenario 13, whereby the intervention 
under consideration has a cost-effectiveness profile which is better than many 
interventions currently funded by the NHS, incremental costs and effects are subject to 
only a low degree of uncertainty and no other therapies are available. 
 
Interestingly, less consistency is observed for some scenarios, for example scenario 10 
and scenario 14, for which around half of the respondents stated that they would 
recommend the intervention under consideration, whilst the remainder stated that they 
would not. For these scenarios, either the incremental cost per QALY gained is less 
favourable, or incremental costs and effects are subject to a high degree of uncertainty.  
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4.2.3 Assessment of internal consistency 
Table 10 presents the results of the assessment of logical consistency of the Appraisal 
Committee responses, as described in Section 3.7.1. 
 
Table 10  Logical consistency of response data 
Scenario comparison Number logically consistent (%) Number inconsistent (%) 
Scenario 2 versus 11 35 (97.22%) 1 (2.78%) 
Scenario 7 versus 16 37 (100%) 0 (0%) 
Scenario 5 versus 18 37 (100%) 0 (0%) 
Scenario 10 versus 12 36 (97.3%) 1 (2.70%) 
 
For the four scenario comparisons presented in Table 10, the data suggests almost 
complete logical consistency for individual responses. Only 2 of the 147 respondent-
level comparisons which could be assessed were found to be logically inconsistent. 
 
4.3 Results of logit regression modelling 
Table 11 presents the results of the logit regression model; parameter values are 
expressed both in terms of model coefficients (the natural log of the odds ratio) and 
standardised odds ratios. The odds ratios describe the reduction in the odds of adoption 
associated with moving from the base attribute level to the selected attribute level.  
 
Table 11 Results of logit regression model 
Model parameter Coefficient (log odds) 
Odds 
ratio 
Robust 
standard 
error 
Significance 
(p) 
Lower 
95% c.i. 
Upper 
95% c.i. 
Cost per QALY 
gained level 1 
(£25,000) 
-1.7823 0.1683 0.3434 0.0000 -2.4554 -1.1092 
Cost per QALY 
gained level 2 
(£35,000) 
-4.0771 0.0170 0.4237 0.0000 -4.9076 -3.2467 
Uncertainty level 1 
(high) -1.1624 0.3127 0.2278 0.0000 -1.6089 -0.7160 
Age level 1 (working) 0.1391 1.1492 0.1830 0.4470 -0.2197 0.4978 
Age level 2 (retired) 0.0752 1.0781 0.2609 0.7730 -0.4362 0.5865 
HRQoL level 1 (0.50) 0.0183 1.0185 0.2205 0.9340 -0.4139 0.4506 
HRQoL level 2 (0.75) -0.7327 0.4806 0.2480 0.0030 -1.2187 -0.2467 
Other therapies level 1 
(yes) -1.5292 0.2167 0.2688 0.0000 -2.0561 -1.0024 
Constant 4.1471 - 0.4305 0.0000 3.3033 4.9908 
 
  46
   
The logit model suggests that increases in cost-effectiveness, uncertainty, and the 
availability of other therapies are associated with a statistically significant reduction in 
the odds of adoption at the 5% level. In addition, the transition from very low HRQoL 
(0.25) to a comparatively high level of HRQoL (0.75) is also statistically significant. 
The model suggests that small changes in HRQoL (utility of 0.25-0.50), and the age of 
the target population are not associated with a statistically significant reduction in the 
odds of a positive recommendation (p>0.05). Table 11 suggests that an increase in 
incremental cost-effectiveness from £15,000 to £25,000 per QALY gained, the odds of 
a positive recommendation are multiplied by 0.1683 (a dramatic 83% decrease). 
Switching from an incremental cost-effectiveness of £15,000 to £35,000 per QALY 
further reduces the odds of a positive recommendation by a factor of 0.0170 (a 98% 
decrease). The analysis suggests that switching from a low level of uncertainty to a high 
level of uncertainty reduces the odds of a positive recommendation by a factor of 
0.3127 (a 69% decrease). Moving from interventions which are aimed at patients with 
low baseline HRQoL (0.25) to high baseline HRQoL (0.75) is associated with a 
reduction in the odds of a positive recommendation of 52%. The model also suggests 
that switching from interventions targeted at diseases and conditions where other 
effective therapies are already available to best supportive care is associated with a 
reduction in the odds of adoption of 78%.  
 
The overall goodness of fit indicated by the pseudo r-squared value was 0.35; Louviere 
et al suggests that for nonlinear models, a pseudo r-squared value of between 0.2 and 
0.4 indicates an adequate model fit.48 Whilst it would be beneficial to test the goodness 
of fit of the regression model using a statistical method such as the chi-squared test, this 
is inappropriate due to the inclusion of adjustments for within-respondent clustering 
effects (Personal communication, Dr Stephen Walters, Senior Lecturer in Medical 
Statistics, Health Economics and Decision Science Section, University of Sheffield). 
 
4.4 Assessment of explanatory power  
In order to test the explanatory power of the model, the probability of adoption for each 
of the eighteen scenarios was estimated using both the random effects logit model (as 
described in Section 4.3) and its equivalent probit counterpart. The results of these two 
regression models were then compared to the observed probabilities of adoption 
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observed within the response data. Figure 4 suggests that both the logit and probit 
models closely predict the observed response data. The comparison suggests very minor 
predictive differences between the probit and logit estimations. 
 
Figure 4  Observed versus expected probabilities of “yes” response  
 
 
4.5 Sensitivity analysis  
As noted in Section 3.4.3.5, interpretation of the Appraisal Committee members’ 
preferences may be problematic due to the use of the “other therapies” attribute; those 
scenarios in which the comparator is described as best supportive care suggest a 
different baseline to those scenarios in which other therapies are already available to 
manage the disease or condition. In other words, the therapy the respondent is assumed 
to prefer if they reject the intervention under consideration is different depending on the 
nature of the comparator. To explore the impact of this potential confounding, a 
separate logit model was estimated for those choice scenarios in which other therapies 
were available, as shown in Table 12.  
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Table 12  Logit regression results for scenarios where comparator is “other 
therapies available” compared to logit results for all scenarios   
Other therapies available scenarios 
(n=12) 
All scenarios  
(n=18) Model parameter 
 Coefficient Odds 
ratio 
P (sig) Coefficient Odds 
ratio 
P (sig) 
Cost per QALY 
gained level 1 
(£25,000) 
-1.4092 0.2443 0.0010 -1.7823 0.1683 0.0000 
Cost per QALY 
gained level 2 
(£35,000) 
-4.3335 0.0131 0.0000 -4.0771 0.0170 0.0000 
Uncertainty level 1 
(high) -1.0636 0.3452 0.0010 -1.1624 0.3127 0.0000 
Age level 1 
(working) 0.2440 1.2764 0.2850 0.1391 1.1492 0.4470 
Age level 2 (retired) -0.1903 0.8267 0.6100 0.0752 1.0781 0.7730 
HRQoL level 1 
(0.50) 0.6026 1.8268 0.2090 0.0183 1.0185 0.9340 
HRQoL level 2 
(0.75) -0.7159 0.4888 0.0060 -0.7327 0.4806 0.0030 
Constant 2.3271 - 0.0000 4.1471 - 0.0000 
 
Table 12 suggests only minor differences in the impact of individual attribute levels on 
the odds of adoption. For those scenarios in which other therapies were available, the 
incremental cost per QALY gained, uncertainty, and age attributes appear to remain 
largely unaffected. Notably, the odds ratio for the change in baseline HRQoL from level 
0 (0.25) to level 1 (0.50) is nearly double the estimate from the main analysis (1.8268 
vs. 1.0185). This appears to be a slightly perverse result, as one would expect the odds 
ratio to be below 1.0, however, this change in odds is not statistically significant in 
either analysis (p>0.05). This sensitivity analysis suggests that only negligible 
interactions exist between the “other therapies” attribute and the other attributes 
included in the experiment. Unfortunately, due to the design of the experiment and the 
decision to maintain orthogonality at the cost of balance, only six choices scenarios 
described interventions for which the comparator was best supportive care. 
Consequently, insufficient data were available to estimate the parameters to a regression 
model describing these scenarios alone.  
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4.6 External validity: Comparison of stated preference and revealed 
preference data  
Table 13 shows extracted data on the five attributes included in the model, together with 
the resulting appraisal determination for each of the seven case study technology 
appraisals. Data sources used to inform the parameter assumptions used in the model 
are shown in brackets. 
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Table 13  Revealed preference attribute levels and adoption decisions for the seven case study appraisals 
 
Appraisal Cost per QALY Uncertainty Age Baseline HRQoL 
Other 
therapies 
available? 
Adoption 
decision 
(1) Clopidogrel for non-ST-
segment-elevation acute 
coronary syndrome (No. 
80)66  
All cost per QALY estimates 
reported in NICE guidance 
<£15,000 per QALY 
gained.66 Level 0 
(CPQ=£15,000) assumed. 
0.72 probability of being optimal 
at £10,000 per QALY gained.66 
Level 0 (low uncertainty) 
assumed. 
Clinical evidence 
obtained from 
individuals aged 
66-68 years of 
age.66 Level 2 
(Retired) used in 
model.  
Utility of 0.80 
used in health 
economic 
model.67 Level 2 
(0.75) used in 
logit model.   
Yes Yes 
(2) Routine antenatal anti-D 
prophylaxis for RhD-
negative women (No. 41)68 
Incremental cost per QALY 
=£7,600 for primigravidae vs. 
post-partum, and £28,000 for 
All rhesus-negative vs. 
primigravidae reported in 
NICE guidance.68 Level 0 
(CPQ=£15,000) assumed.  
High uncertainty due to absence 
of information on QALYs lost 
due to fetal/neonatal loss.68 Level 
1 (high uncertainty) assumed.  
Working age 
assumed. 
Level 2 (0.75) 
assumed. 
No Yes 
(3) Anakinra for 
rheumatoid arthritis 
(No.72)69 
Using the Appraisal 
Committee’s preferred 
biologics, Assessment model 
estimates > £67,000 per 
QALY gained.69 Level 2 
(£35,000 per QALY gained) 
assumed in model.  
NICE guidance notes 
considerable uncertainty 
surrounding parameter values.69 
Level 1 assumed (high 
uncertainty)  
Working age 
assumed from 
evidence in 
Assessment 
Report.70  
No information 
available. Utility 
of 0.25 assumed. 
Yes No 
(4) Rituximab for 
aggressive non-Hodgkin’s 
lymphoma (No. 65)71 
All cost per QALY estimates 
reported in guidance 
<£15,000 per QALY 
gained.71 Level 0 assumed 
(£15,000 per QALY gained). 
PSA indicated 
5% chance that the cost per 
QALY would exceed 
£23,400 in people aged > 60, or 
£19,000 in people < 60 years.71 
Level 0 assumed. 
Retired age 
assumed as 
clinical evidence 
relates to 
individuals aged 
60-80.71 
Utility scores 
reported in 
Assessment 
Report >0.75. 
Level 2 assumed 
(0.75).72 
Yes Yes 
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(5) Liquid-based cytology 
for cervical screening (No. 
69)73  
Base case analysis suggested 
CPQ=<£10,000 per QALY 
gained.73 Level 0 assumed 
(£15,000 per QALY).  
High uncertainty assumed from 
Assessment Report; notably due 
to lack of good quality sensitivity 
and specificity studies and 
importance of these parameters 
in the model.74 
Working age 
assumed. 
General 
population 
utility assumed. 
Level 2 assumed 
(0.75). 
No Yes 
(6) Beta Interferon and 
Glatiramer Acetate for the 
treatment of Multiple 
Sclerosis (No. 32)75 
Base case cost-effectiveness 
>£40,000 per QALY 
gained.75 Level 2 assumed in 
model (£35,000 per QALY 
gained).  
PSA suggested considerable 
parametric uncertainty. Time 
horizon identified as central 
determinant of cost-
effectiveness.76 
Working age 
assumed. 
Utility of 0.5 
assumed.76 
No No 
(7) Ribavirin and Interferon 
Alpha for Hepatitis C (No. 
41)77 
Cost/QALY gained from 
treatment with combination 
therapy for 6 months in 
comparison with 
monotherapy estimated to be 
£7,000. Following relapse 
after previous course of 
interferon alpha, CPQ from 6 
months of combination 
therapy compared with 
monotherapy estimated to be 
£3,050.77 Level 0 assumed 
(£15,000per QALY gained).  
High uncertainty assumed. Working age 
assumed 
0.75 assumed 
from Harvard 
Preference 
Scores.65 
No Yes 
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A series of scenarios were generated based upon the information detailed in Table 13; 
these data were then inputted into the logit regression model. Table 14 shows the 
resulting estimated probability of adoption for each of the scenarios. 
 
Table 14  Results of the assessment of criterion validity  
Technology 
appraisal 
 
Incremental 
cost per 
QALY 
gained 
Uncertainty Age HRQoL Other therapies 
NICE 
decision 
 
P(adopt) 
 
Clopidogrel for 
non-ST-
segment-
elevation acute 
coronary 
syndrome 
£15,000 Low Retired 0.75 Yes Yes 0.88 (yes) 
Routine 
antenatal anti-D 
prophylaxis for 
RhD-negative 
women 
£15,000 High Working 0.25 No Yes 0.96 (yes) 
Anakinra for 
rheumatoid 
arthritis 
£35,000 High Working 0.25 Yes No 0.08 (no) 
Rituximab for 
aggressive non-
Hodgkin’s 
lymphoma 
£15,000 Low Retired 0.25 Yes Yes 0.94 (yes) 
Liquid-based 
cytology for 
cervical 
screening 
£15,000 Low Working 0.25 No Yes 0.99 (yes) 
Beta interferon 
and glatiramer 
acetate for 
multiple 
sclerosis 
£35,000 High Working 0.50 No No 0.28 (no) 
Ribavirin and 
interferon alpha 
for Hepatitis C 
£15,000 High Working 0.25 Yes Yes 0.83 (yes) 
 
Table 14 suggests that the model is capable of distinguishing between those 
technologies which the Appraisal Committees would be highly likely to recommend, 
and those technologies which appear to be less attractive. It should be noted however, 
that the two rejections were for interventions which had less attractive cost-effectiveness 
profiles (£35,000 per QALY gained). An important question therefore is “what other 
factors must be present for a less cost-effective intervention to become viable for 
recommendation?” For interventions with an incremental cost-effectiveness of £35,000 
per QALY gained, the highest probability of adoption that could be obtained from the 
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model was 0.56 (assuming low uncertainty, working age, no therapies available, low 
baseline quality of life). For interventions which have an incremental cost-effectiveness 
of £25,000 per QALY gained, the equivalent scenario suggests a much higher potential 
probability of adoption (0.93). Thus, the model suggests that it is possible for 
interventions which have weaker cost-effectiveness profiles to be viable for adoption; 
between £25,000 and £35,000 per QALY gained, the differential impact of these other 
factors on the probability of adoption may be substantial. 
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Chapter 5 Discussion 
5.1 Discussion of study findings 
The results of the stated preference modelling suggest that incremental cost-
effectiveness, the degree of uncertainty surrounding incremental costs and effects, the 
baseline HRQoL of the target patient group and the availability of other therapies are 
significant factors which influence the Appraisal Committees’ decisions whether to 
recommend health technologies. Interestingly, the results of the stated preference 
modelling appear to support the Institute’s recent dissemination of draft guidelines on 
social value judgements,5;64 as the modelling suggests that the age of the target 
population is not associated with an additional equity weighting. 
 
The modelling exercise presents compelling evidence in support of Rawlins and 
Culyer’s3 probabilistic adoption/rejection curve, rather than the operation of a single 
threshold value. The analysis suggests for interventions which have a less attractive 
cost-effectiveness profile of £25,000 per QALY gained and £35,000 per QALY gained, 
the odds of a positive recommendation are substantially reduced by a factor of 0.8317 
(p=0.000) and 0.9830 (p=0.000) respectively. Interestingly, the “mythical” £30,000 per 
QALY gained cost-effectiveness threshold is not supported by this stated preference 
modelling analysis. Rather, the stated preference modelling suggests that the Institute’s 
Appraisal Committees would be unlikely to adopt technologies with this level of cost-
effectiveness unless other factors are present, for example those diseases in which 
patients have a very low baseline quality of life, or diseases for which no established 
effective therapies are available. The results of the modelling exercise appear to contrast 
with the findings of Devlin and Parkin’s analysis of revealed preference data from NICE 
guidance,23 which suggested that the Institute’s Appraisal Committees operated a 
substantially higher cost-effectiveness threshold of between £35,000-£57,000.†  
 
The modelling analysis suggests that the presence of a high degree of uncertainty also 
significantly influences the Committees’ decision to adopt health technologies. The 
model suggests that switching from a low level of uncertainty to a high level of 
uncertainty around incremental costs and effects reduces the odds of adoption by around 
69% (p=0.000). Switching from interventions which are targeted at individuals who 
have a low level of HRQoL prior to receiving treatment (utility score=0.25) to those 
† Mean values from reported probabilistic threshold models 
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interventions which are targeted at individuals who are comparatively healthy (utility 
score=0.75) leads to a reduction in the odds of adoption of 52% (p=0.003). The 
existence of other therapies to treat diseases is associated with a reduction in the odds of 
adoption of 78% compared to interventions used to manage diseases for which the only 
available therapy is best supportive care.  
 
The evidence of trading between attributes within the response data suggests that the 
attributes and levels selected for use in the study were broadly appropriate. Interestingly, 
one of the study respondents commented that the use of a higher cost-effectiveness level 
of £40,000 per QALY gained would represent more difficult choices, however, the 
dramatic reduction in the odds of adoption associated with switching from £15,000 to 
£35,000 per QALY gained suggests that this would have little impact upon the model.  
 
Both the logit and probit regression models provided a good fit to the elicited response 
data. Exploratory sensitivity analysis using only those choice scenarios which compared 
the intervention under consideration to some established therapy (Scenarios numbered 1, 
2, 4, 5, 7, 9, 10, 11, 12, 15, 16 and 18) did not indicate the presence of confounding due 
to differences in the comparator treatment option the respondent is assumed to prefer if 
they reject the intervention under consideration. The analysis of logical consistency 
suggested that the choice responses elicited from individual Committees members were 
on the whole, internally consistent, although it should be noted that this test only 
covered two of the attributes (HRQoL and incremental cost-effectiveness). The 
comparison of the stated preference model against the revealed preference data reported 
within the seven NICE guidance reports and Assessment Reports indicates a potentially 
high degree of external validity, although further comparisons between the stated 
preference and revealed preference data are warranted.  
 
5.2 Limitations of the study 
The results of this choice experiment should be considered exploratory rather than 
definitive, as the decisions faced by the Appraisal Committees are invariably more 
complex than the scope of the choice experiment presented here. Indeed, the utility of 
the preference model is restricted by the limited number of attributes included in the 
experiment, and the limited number of levels used to describe each attribute. As 
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suggested in Chapter 3, it could have been preferable to include additional attributes in 
order to explain more variation in the elicited responses. For example, one respondent 
suggested that the expected size of the clinical benefit would have been an appropriate 
attribute for inclusion in the experiment (Personal communication, Dr Richard 
Cookson, Senior Lecturer in Health Economics / member of NICE Appraisals 
Committee, University of York), or perhaps an attribute could have been included to 
describe whether the intervention under consideration saves lives, improves HRQoL, or 
both. However, these factors should already be incorporated into the incremental cost 
per QALY gained attribute.  
 
Whilst the analysis suggests that the selected attributes and levels were capable of being 
traded off against one another, greater precision in the elicited preferences could be 
realised through introducing a larger number of levels used to describe the attributes. 
For example, using a range from £10,000 to £40,000 per QALY gained, perhaps 
increasing in increments of £5,000 per QALY gained, could provide more sensitive 
estimates of the Committees’ preferences for incremental cost-effectiveness.  
 
Despite the simplicity of the experiment, as acknowledged above, it was felt that the 
attributes and levels selected for inclusion would provide a parsimonious model which 
included the key factors which influence decisions concerning the adoption of health 
technologies. However, it should also be noted that due to the limited number of 
potential responders (81 NICE Appraisal Committee members) and the disproportionate 
increase in the cognitive burden resulting from the inclusion of additional attributes and 
levels, it was necessary to trade-off certain aspects of the ideal experiment design 
against a design which would maximise response rates whilst maintaining a reasonable 
degree of precision. Despite these practical considerations, the experiment successfully 
managed to explore the key trade-offs between incremental cost-effectiveness, 
uncertainty and relevant equity concerns.  
 
It should also be noted that the number of choice scenarios presented to each respondent 
within the questionnaire was less than the number currently recommended within the 
literature.48 Whilst the inclusion of a larger number of scenarios within the choice 
questionnaire could potentially improve the precision of the coefficients estimated by 
the regression model, it is likely that adherence to current recommendations for stated 
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preference designs would have substantially reduced the already limited response rate. 
Consequently, the preferences presented here should be interpreted as exploratory rather 
than precise estimates. 
  
A further limitation of the study concerns the description of the scenarios used within 
the choice experiment. The interpretation of the uncertainty attribute within the study 
was purposefully subjective; different interpretations of this attribute and its associated 
levels may have led to some bias in the results. For example, uncertainty surrounding 
the incremental costs and effects of an intervention may be large, yet the probability that 
the intervention is optimal at a given willingness to pay threshold may be high. It is 
therefore important to note that the potential difference between parametric uncertainty 
and decision uncertainty is not captured by this experiment. Furthermore, the description 
of the uncertainty attribute does not include information concerning whether the 
intervention is potentially dominated by the current standard treatment. Consequently, 
some respondents may have assumed that incremental costs and effects always lie in the 
North-West quadrant of the cost-effectiveness plane (i.e. the intervention is more 
effective but more costly than the current treatment), whilst others may have assumed 
that the intervention under consideration may be potentially dominated by the current 
standard treatment. It is likely that these two alternative interpretations would affect 
respondents’ preferences differently. As noted in Chapter 3, the use of a range to 
describe the uncertainty in incremental net benefits would have been more appropriate 
from a theoretical perspective, although this would have reduced the face validity of the 
experiment  
 
It should also be noted that the description of the uncertainty attribute used within this 
experiment focuses only on parametric uncertainty, and assumes that all relevant 
parameter uncertainty is appropriately modelled. However, the Appraisal Committees 
may also consider the impact of structural and methodological uncertainties on cost-
effectiveness estimates (Personal communication, Louise Longworth, Technical 
Analyst, Centre for Health Technology Evaluation, NICE, London).  
 
It should noted once more that the stated preference data elicited from the Appraisal 
Committee members represents the preferences of individuals, and therefore cannot 
capture the dynamics of organisational decision-making. In addition, the choice data 
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used within the experiment represent the choices that the Appraisal Committee members 
say they would make, and as such may not reflect the actual decisions that the 
Committees would make in reality. 
 
The principal limitation of the analysis of the preference data concerns the relatively low 
response rate (46%). Whilst sufficient observations were obtained for use in the 
regression modelling, there is a chance that the preferences elicited may not be 
representative of the Appraisal Committees as a whole. Whilst the questionnaire did not 
request personal information from study participants, personal correspondence from 
some of the study respondents suggested that participating Committee members varied 
in terms of their professional background (including statisticians, health economists, and 
clinicians).  
 
A final limitation is that the use of a fractional factorial main effects design and a simple 
additive regression model is likely to account for only around 70-90% of the explained 
variance.48 The inclusion of two-way or higher-order interactions between attribute 
levels could potentially account for further explained variance, albeit at the cost of a 
greater number of degrees of freedom and the potential under-determination of the 
model. However, the literature suggests that models derived from main effects only 
designs often predict well in attribute regions of greatest interest even if their parameters 
are biased.48  
 
5.3 Areas for further research 
A number of areas for further research are merited: 
· The case study technology appraisals used to assess the external validity of the 
preference model represent only a small proportion of the total number of 
appraisals undertaken by NICE to date. Systematic analysis of all existing 
revealed preference data using the choice model developed within this study 
could be used to further assess the model’s external validity. In addition, 
discrepancies between the predicted outcomes from the model and the actual 
recommendations published within NICE guidance may provide some indication 
of the impact of group decision-making phenomena on the recommendations for 
the use of technologies issued by the Institute. 
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· The inclusion of other potential equity concerns, for example, distinctions 
between those technologies which are life-saving and those which are HRQoL-
gaining, could be explored within a similar experiment. 
· It would be interesting to explore the consistency between the preferences of the 
members of the Institute’s Centre for Health Technology Evaluation and its 
Appraisal Committees. An extension study to address this research question is 
currently underway; the results of this analysis will be forthcoming. 
· Finally, it would be particularly interesting to understand how NICE’s health 
care decision-making criteria differ from those used by other health care 
commissioning groups such as the Scottish Medicines Consortium (SMC), the 
Australian Pharmaceutical Benefits Advisory Committee (PBAC), and the 
Canadian Co-ordinating Office for Health Technology Assessment (CCOHTA). 
For the purposes of comparability, this extension study could be undertaken 
using the same design as the NICE study.  
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6. Conclusion 
The results of the stated preference modelling suggests that incremental cost-
effectiveness, the degree of uncertainty surrounding incremental costs and effects, the 
baseline HRQoL of the target patient group and the availability of other therapies are 
significant factors which influence the NICE Appraisal Committees’ decisions 
concerning the recommendation for or against the use of health technologies.  
 
 
   
  61
   
References 
 
 
 1.  Department of Health. The New NHS. Modern. Dependable. White Paper. 1997. 
London, The Stationary Office.  
 2.  National Institute for Clinical Excellence. A guide to NICE. 1-34. 2005. London, 
NICE.  
 3.  Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value 
judgements. British Medical Journal 2004;329:224-7. 
 4.  Rawlins MD. Scientific and social value judgements. 2004: 1-20. London, NICE.  
 5.  Rawlins MD. Social value judgements: Guidelines for the Institute and its 
advisory bodies. Draft for consultation. 2005:1-31. London, NICE.  
 6.  A National Health Service. 1944. London, HMSO.  
 7.  Fuchs VR. Who shall live? Health, Economics and Social Choice. London: World 
Scientific, 1998. 
 8.  Sculpher M, Drummond M, O'Brien B. Effectiveness, efficiency, and NICE. 
British Medical Journal 2001;322:943-4. 
 9.  Smith R. The failings of NICE. British Medical Journal 2000;321:1363-4. 
 10.  Hutton J,.Maynard A. A NICE challenge for health economics. Health Economics 
2000;9:89-93. 
 11.  National Institute for Clinical Excellence. Legal context of NICE guidance. 2005. 
London, NICE.  
 12.  National Institute for Clinical Excellence. Guide to the Technology Appraisals 
Process. 1-31. 2004. London, NICE.  
 13.  National Institute for Clinical Excellence. Guide to the methods for technology 
appraisal. 2004:1-71. London, NICE.  
   
  62
   
 14.  Pritchard C. Overseas approaches to decision making. In Towse A, Pritchard C, 
Devlin N, eds. Cost-effectiveness thresholds, pp 56-68. London: King's Fund / 
Office for Health Economics, 2002. 
 15.  Loewry EH. Cost Should Not Be a Factor in Medical Care [editorial]. New 
England Journal of Medicine 1980;302:697. 
 16.  Eddy DM. A manual for assessing health pratices and designing practice policies: 
an explicit approach. Philadelphia: Oxford University Press, 1992. 
 17.  Weinstein MC,.Stason WB. Foundations of cost-effectiveness analysis for health 
and medical practices. New England Journal of Medicine 1977;296:716-21. 
 18.  Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: More harm 
than good? Social Science and Medicine 1993;37:33-40. 
 19.  Gold M, Siegel JE, Russell LB, Weinstein MC (eds). Cost-Effectiveness in Health 
and Medicine. New York: Oxford University Press , 1996. 
 20.  Cookson R, McDaid D, Maynard A. Wrong SIGN, NICE mess: is national 
guidance distorting allocation of resources? British Medical Journal 2001;323:743-
5. 
 21.  Miners AH, Garau M, Fidan D, and Fischer AJ. Comparing estimates of cost 
effectiveness submitted to the National Institute for Clinical Excellence (NICE) by 
different organisations: retrospective study. British Medical Journal 2004:330.  
 22.  Birch S, Gafni A. On being NICE in the UK: guidelines for technology appraisal 
for the NHS in England and Wales. Health Economics 2002;11:185-91. 
 23.  Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what 
other factors influence its decisions? A binary choice analysis. Health Economics 
2004;13:437-52. 
 24.  Hill S, Garattini S, van Loenhout J, O'Brien BJ, and de Joncheere K. Technology 
Appraisal Programme of the National Institute for Clinical Excellence: A review 
by WHO. 2003. World Health Organisation.  
   
  63
   
 25.  Littlejohns P. Does NICE have a threshold? A response. In Towse A, Pritchard C, 
Devlin N, eds. Cost-effectiveness thresholds, pp 31-7. London: King's Fund / 
Office for Health Economics, 2002. 
 26.  National Institute for Clinical Excellence. Supplementary evidence to the House of 
Commons Health Select Committee. Paper 2. 2002:1-9. London, NICE.  
 27.  National Institute for Clinical Excellence. Guidance on the use of orlistat for the 
treatment of obesity in adults. Guidance no.22. 2001:1-12. London, NICE.  
 28.  Raftery J. NICE: Faster access to modern treatments? Analysis of guidance on 
health technologies. British Medical Journal 2001;323:1300-3. 
 29.  National Institute for Clinical Excellence and Nation. Guidance on the use of 
riluzole (Rilutek) for the treatment of motor neurone disease. Guidance no. 20. 
2001:1-10. London, NICE.  
 30.  Williams A. What could be NICER than NICE? Office for Health Economics 
Annual Lecture 2004. 
 31.  Briggs AH,.Gray AM. Handling uncertainty when performing economic 
evaluations of healthcare interventions. Health Technology Assessment 1999;3:i-
134. 
 32.  Claxton K. The irrelevance of inference: a decision-making approach to the 
stochastic evaluation of health care technologies. Journal of Health Economics 
1999;18:341-64. 
 33.  Claxton K, Sculpher M, Drummond M. A rational framework for decision making 
by the National Institute for Clinical Excellence (NICE). The Lancet 
2002;360:711-5. 
 34.  Yamey G. Chairman of NICE admits that its judgements are hard to defend. 
British Medical Journal 1999;319:1222. 
 35.  Dobson F. Secretary of State's speech launching the National Institute for Clinical 
Excellence. 31st March 1999. Available from: 
   
  64
   
http://www.nice.org.uk/embcat.aspx?page=oldsite/back/frank_dobson.htm 
[Accessed 02/04/2005].  
 36.  Culyer AJ. Equity—some theory and its policy implications. Journal of Medical 
Ethics 2001;27:275-83. 
 37.  Culyer AJ. Economics and ethics in health care. Journal of Medical Ethics 
2001;27:217-22. 
 38.  Dolan P, Olsen JA. Distributing health care: Economic and ethical issues. New 
York: Oxford University Press, 2002. 
 39.  Rawls J. A theory of justice. Cambridge, Massachusetts: Harvard University Press, 
1971. 
 40.  Harris J. Unprincipled QALYs - a response to Cubbin. Journal of Medical Ethics 
1991;17:185-8. 
 41.  Williams A. Intergenerational equity: an exploration of the 'fair innings' argument. 
Health Economics 1997;6:117-32. 
 42.  Nord E. Cost-value analysis in health care: Making sense out of QALYs. 
Cambridge: Cambridge University Press, 1999. 
 43.  Jonsen AR. Bentham in a box: technology assessment and health care allocation. 
Law, Medicine and Health Care 1986;14:172-4. 
 44.  LeGrand J. Equity, health and health care. Social Justice Research 1987;1:257-74. 
 45.  Dolan P, Shaw R, Tsuchiya A, Williams A. QALY maximisation and people's 
preferences: a methodological review of the literature. Health Economics 
2005;14:197-208. 
 46.  Dolan P, Tsuchiya A, Brazier J, and Ratcliffe J. Social QALY Project: Summary.  
2005. Available from http://www.shef.ac.uk [Accessed 23/05/2005].  
 47.  Ratcliffe J. Valuing the benefits of health care technologies: a case study of liver 
transplantation. PhD Thesis. 2000. London, Health Economics Research Group, 
Brunel University.  
   
  65
   
 48.  Louviere J, Hensher D, Swait J. Stated choice methods: Analysis and application. 
Cambridge, UK: Cambridge University Press, 2000. 
 49.  Ryan M. Using Consumer Preferences in Health Care Decision Making: the 
Application of Conjoint Analysis. 1996. London, OHE Publications.  
 50.  Kocur G, Alder T, , Hyman W, and Aunet B. A guide to forecasting travel demand 
with direct utility assessment. 1982. Washington DC, US Department of 
Transportation.  
 51.  Bates J. Sensitivity to level of service: Evidence from stated preference work. 
Research for Transport Policy 1986;13:289-305. 
 52.  Wardman M. Route choice and the value of motorists travel time: empirical 
findings. Institute for Transport Studies Working Paper 224. 1986. University of 
Leeds.  
 53.  Magat WA, Viscusi WK, Huber J. Paired comparison and contingent valuation 
approaches to morbidity risk valuation. Journal of Environmental Economics and 
Management 1988;15:396-411. 
 54.  Yoo DI,.Ohta H. Optimal pricing and product planning for new multiattribute 
products based on conjoint analysis. International Journal of Production 
Economics 1995;38:245-53. 
 55.  Dennis DF. Analysing public inputs to multiple objective decisions on national 
forests using conjoint analysis. Forest Science 1998;44:421-9. 
 56.  Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients' 
preferences for the management of non-metastatic prostate cancer: discrete choice 
experiment. British Medical Journal 2004;328. 
 57.  Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. 
British Medical Journal 2000;320:1530-3. 
 58.  Propper C. Contingent valuation of time spent on NHS waiting lists. The 
Economic Journal 1991;100:193-9. 
   
  66
   
 59.  Ubach C, Scott A, French F, Awramenko, M, Needham G. What do hospital 
consultants value about their jobs? A discrete choice experiment. British Medical 
Journal 2003;326. 
 60.  Ryan M. Using conjoint analysis to take account of patient's preferences and go 
beyond health outcomes. An application to in-vitro fertilisation. Social Science 
and Medicine 1999;48:535-46. 
 61.  Von Neumann J, Morgenstern O. Theory of Games and Economic Behavior. 
Princeton University Press, New Jersey, 1944. 
 62.  Beach LR. The Psychology of Decision-Making. London: Sage, 1997. 
 63.  Miller GA. The Magical Number Seven, Plus or Minus Two: Some Limits on Our 
Capacity for Processing Information. The Psychological Review 1956;63:81-97. 
 64.  Mayor S. NICE says that patients' age should affect treatment. British Medical 
Journal 2005;330:1102. 
 65.  Harvard Center for Risk Analysis. Catalog of Preference Scores. 2005.  
 66.  National Institute for Clinical Excellence. Clopidogrel in the treatment of non-ST-
segment-elevation acute coronary syndrome. Technology Appraisal Guidance 80.  
2004. London, NICE.  
 67.  Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al. A rapid and 
systematic review of the clinical effectiveness and costeffectiveness of clopidogrel 
used in combination with aspirin compared to aspirin alone in the treatment of 
non-ST-segment-elevation acute coronary syndromes (ACS). Technology 
assessment report prepared for the National Institute for Clinical Excellence, 
2003:1-180.  
 68.  National Institute for Clinical Excellence. Guidance on the use of routine antenatal 
anti-D prophylaxis for RhD-negative women. Technology Appraisal Guidance No. 
41. 2002. London, NICE.  
 69.  National Institute for Clinical Excellence. Anakinra for rheumatoid arthritis. 
Technology Appraisal Guidance 72. 2003. London, NICE.  
   
  67
   
 70.  Clark W, Jobanputra P, Barton P, and Burls A. The clinical and cost-effectiveness 
of anakinra for the treatment of rheumatoid arthritis in adults. Technology 
Assessment Report prepared for the National Institute for Clinical Excellence, 
2003:1-117.  
 71.  National Institute for Clinical Excellence. Rituximab for aggressive non-Hodgkin's 
lymphoma. Technology Appraisal 65. 2003. London, NICE.  
 72.  Knight C, Hind D, Brewer N, and Abbott V. Rituximab (MabThera) for aggressive 
non Hodgkin's lymphoma: systematic review. Technology Assessment Report 
prepared for the National Institute for Clinical Excellence, 2003:i-81.  
 73.  National Institute for Clinical Excellence. Guidance on the use of liquid-based 
cytology for cervical screening. Technology Appraisal Guidance 69. 2003. 
London, NICE.  
 74.  Karnon J, Peters J, Platt J, Chilcott J, and McGoogan E. Liquid-based cytology in 
cervical screening: an updated rapid and systematic review. Technology 
Assessment Report prepared for the National Institute for Clinical Excellence, 
2003:i-67.  
 75.  National Institute for Clinical Excellence. Beta interferon and glatiramer acetate 
for the treatment of multiple sclerosis. Technology Appraisal Guidance 32. 2002. 
London, NICE.  
 76.  Tappenden P, Chilcott J, O'Hagan A, McCabe C, Cooper N, Abrams K, and et al. 
Cost effectiveness of beta interferons and glatiramer acetate in the management of 
multiple sclerosis. Technology Assessment Report prepared for the National 
Institute for Clinical Excellence, 2001:i-51.  
 77.  National Institute for Clinical Excellence. Guidance on the use of Ribavirin and 
Interferon Alpha for Hepatitis C. 2003. London, NICE.   
 
   
  68
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examine NICE’s decision-making criteria 
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A discrete choice experiment to 
examine the criteria used in 
health services commissioning 
decisions  
 
 
 
 
 
 
 
 
 
Choice questionnaire 
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Information for study participants 
 
A research group at the School of Health and Related Research (ScHARR) within the 
University of Sheffield is undertaking a study on the importance that health services 
decision-makers place on the various attributes of health interventions when deciding 
whether to commission them. We are interested in the importance that you place on 
central estimates of cost-effectiveness, uncertainty, age, disease severity and the 
availability of alternative therapies. This project is being internally funded by ScHARR 
as part of a postgraduate qualification. 
 
Enclosed is a questionnaire on this issue, which will take ten to fifteen minutes to 
complete. For each the eighteen hypothetical scenarios, we would like you to decide 
whether or not you would be likely to recommend the intervention. Please indicate your 
selection by placing a tick in the appropriate box. We are interested in what you think; 
there are no right or wrong answers. Please note that this is a simple experiment and 
only a limited amount of information can be contained within each scenario. Your 
decision whether to recommend the intervention or not should be based only on the 
information available.  
 
We would be grateful if you would complete the questionnaire and consent form, and 
return these to Paul Tappenden in the stamp addressed envelope by 30th June 2005. If 
you have any problems completing the questionnaire, please do not hesitate to contact 
us (Tel: 0114 2220855, email: P.Tappenden@Sheffield.ac.uk). 
 
Once completed questionnaires have been returned to the project team, these will be 
analysed using a form of regression analysis to estimate the importance of each 
decision attribute. The methods and results of the analysis will be submitted as part of 
an academic thesis, and results will be made available to all study participants at this 
stage. Subject to the approval of the National Institute for Health and Clinical 
Excellence (NICE), it is anticipated that the study will be published in a high quality peer 
reviewed journal. Study participants will be acknowledged within any forthcoming 
publications of this study. 
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Key to choice attributes 
 
Mean cost per quality adjusted life year (QALY) gained 
This is the central estimate of cost-effectiveness for the intervention as compared to 
the current standard treatment. This is calculated as the additional cost of the 
intervention compared to the current standard treatment divided by the additional 
benefits of the intervention compared to the current standard treatment. Three levels 
are specified: (1) £15,000 per QALY gained; (2) £25,000 per QALY gained; (3) 
£35,000 per QALY gained. 
 
Degree of uncertainty around mean cost-effectiveness 
This relates to how uncertain the central estimate of cost-effectiveness is. Two levels 
are specified: (1) Low level of uncertainty – limited dispersion of incremental costs 
and benefits; (2) High level of uncertainty – large dispersion of incremental costs and 
QALYs. Illustrative examples of these are shown below.  
 
Age of target population  
The mean age of the population who will benefit from the intervention. Three levels 
are specified: (1) Children, <18 years; (2) Working, 18-64 years; (3) Retired, >64 
years. 
 
Baseline health related quality of life  
The mean health-related quality of life score of patients prior to receiving the 
intervention, whereby “1” represents a state of perfect health and “0” represents 
dead. Three levels are specified: (1) 0.25; (2) 0.50; (3) 0.75. 
 
Are other effective therapies available? 
Whether alternative effective therapies are available to manage the condition or not. 
Two levels are specified: (1) Yes (i.e. comparator is an alternative effective therapy); 
(2) No (i.e. comparator is best supportive care).  
1) Low uncertainty 2) High uncertainty
b b
x x
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0 0
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CHOICE 1 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £25,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness Low level of uncertainty 
Age of target population Working (18-64 years) 
Baseline health-related quality of life 0.75 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 2 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £15,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Working (18-64 years) 
Baseline health-related quality of life 0.50 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 3 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £25,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Working (18-64 years) 
Baseline health-related quality of life 0.50 
Are other effective therapies available? No 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 4 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £35,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Working (18-64 years) 
Baseline health-related quality of life 0.75 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
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CHOICE 5 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £35,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Children (<18 years) 
Baseline health-related quality of life 0.75 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 6 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £15,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Retired (>64 years) 
Baseline health-related quality of life 0.75 
Are other effective therapies available? No 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 7 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £15,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness Low level of uncertainty 
Age of target population Retired (>64 years) 
Baseline health-related quality of life 0.50 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 8 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £25,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Children (<18 years) 
Baseline health-related quality of life 0.50 
Are other effective therapies available? No 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
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CHOICE 9 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £25,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness Low level of uncertainty 
Age of target population Children (<18 years) 
Baseline health-related quality of life 0.25 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 10 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £25,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Retired (>64 years) 
Baseline health-related quality of life 0.25 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 11 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £15,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Working (18-64 years) 
Baseline health-related quality of life 0.25 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 12 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £25,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Retired (>64 years) 
Baseline health-related quality of life 0.75 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
   
  75   
CHOICE 13 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £15,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness Low level of uncertainty 
Age of target population Children (<18 years) 
Baseline health-related quality of life 0.75 
Are other effective therapies available? No 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 14 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £35,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness Low level of uncertainty 
Age of target population Working (18-64 years) 
Baseline health-related quality of life 0.25 
Are other effective therapies available? No 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 15 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £15,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Children (<18 years) 
Baseline health-related quality of life 0.25 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 16 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £35,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness Low level of uncertainty 
Age of target population Retired (>64 years) 
Baseline health-related quality of life 0.50 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
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CHOICE 17 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £35,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Retired (>64 years) 
Baseline health-related quality of life 0.25 
Are other effective therapies available? No 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
CHOICE 18 
Attribute Intervention versus current standard treatment 
Mean cost per QALY gained £35,000 per QALY gained 
Degree of uncertainty around mean cost-effectiveness High level of uncertainty 
Age of target population Children (<18 years) 
Baseline health-related quality of life 0.50 
Are other effective therapies available? Yes 
 
Would you recommend the intervention? (please tick)  Yes 
        No 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for your co-operation. 
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Appendix 2  Study outline presented to 
NICE’s Appraisal Committees  
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Appendix 3  Letter of ethical approval from 
University of Sheffield Research Ethics 
Committee 
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